

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/24811 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/17**

(21) International Application Number: **PCT/US00/27579**

(22) International Filing Date: **5 October 2000 (05.10.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:

60/157,933 6 October 1999 (06.10.1999) US  
60/181,807 11 February 2000 (11.02.2000) US  
60/215,688 30 June 2000 (30.06.2000) US

(71) Applicants (for all designated States except US): **BIO-GEN, INC.** [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US). **APOTEC R & D, S.A.** [CH/CH]; 84, rue du Rhône, CH-1204 Geneva (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SCHNEIDER, Pascal** [CH/CH]; Tuileries 7, CH-1066 Epalinges (CH). **THOMPSON, Jeffrey** [US/US]; 60 Newcomb Road, Stoneham, MA 02180 (US). **CACHERO, Teresa**

[ES/US]; 105 Longwood Avenue, Brookline, MA 02446 (US). **AMBROSE, Christine** [US/US]; 197 Wakefield Street, Reading, MA 01867 (US). **RENNERT, Paul** [US/US]; 278 Ridge Street, Millis, MA 02054 (US).

(74) Agent: **LINKKILA, Timothy, P.**; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:



— With international search report.

[Continued on next page]

(54) Title: **APRIL RECEPTOR (BCMA) AND USES THEREOF**



A



B

(57) Abstract: A receptor in the TNF family is provided: APRIL-R. Chimeric molecules and antibodies to APRIL-R and methods of use thereof are also provided.

WO 01/24811 A1



— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## APRIL RECEPTOR (BCMA) AND USES THEREOF

### FIELD OF THE INVENTION

The present invention relates generally to methods of treatment for cancer. The  
5 methods involve the administration of certain tumor necrosis factor (TNF) antagonists.

### BACKGROUND OF THE INVENTION

Members of the tumor-necrosis factor (TNF) family of cytokines are involved  
in an ever expanding array of critical biological functions. Each member of the TNF  
family acts by binding to one or more members of a parallel family of receptor proteins.  
10 These receptors in turn signal intracellularly to induce a wide range of physiological or  
developmental responses. Many of the receptor signals influence cell fate, and often  
trigger terminal differentiation. Examples of cellular differentiation include  
proliferation, maturation, migration, and death.

TNF family members are Type II membrane bound proteins, having a short  
15 intracellular N-terminal domain, a transmembrane domain, and the C-terminal receptor  
binding domains lying outside the cell surface. In some cases the extracellular portion  
of the protein is cleaved off, creating a secreted form of the cytokine. While the  
membrane bound proteins act locally, presumably through cell contact mediated  
interaction with their receptors, the secreted forms have the potential to circulate or  
20 diffuse, and therefore can act at distant sites. Both membrane bound and secreted  
forms exist as trimers, and are thought to transduce their signal to receptors by  
facilitating receptor clustering.

The TNF receptor protein family is characterized by having one or more  
cysteine rich extracellular domains. Each cysteine rich region creates a disulfide-  
25 bonded core domain, which contributes to the three dimensional structure that forms  
the ligand binding pocket. The receptors are Type I membrane bound proteins, in  
which the extracellular domain is encoded by the N-terminus, followed by a  
transmembrane domain and a C-terminal intracellular domain. The intracellular  
domain is responsible for receptor signaling. Some receptors contain an intracellular  
30 "death domain", which can signal cell apoptosis, and these can be strong inducers of  
cell death. Another class of receptors can weakly induce cell death; these appear to  
lack a death domain. A third class of receptors do not induce cell death. All classes of  
receptors can signal cell proliferation or differentiation instead of death, depending on  
cell type or the occurrence of other signals.

A well studied example of the pluripotent nature of TNF family activity is the nominant member, TNF. TNF can exist as a membrane bound cytokine or can be cleaved and secreted. Both forms bind to the two TNF receptors, TNF-R55 and TNF-R75. Originally described on the basis on its' ability to directly kill tumor cells, TNF  
5 also controls a wide array of immune processes, including inducing acute inflammatory reactions, as well as maintaining lymphoid tissue homeostasis. Because of the dual role this cytokine can play in various pathological settings, both agonist and antagonist reagents have been developed as modifiers of disease. For example TNF and LT $\alpha$  (which also signals through the TNF receptors) have been used in treatment for cancers,  
10 especially those residing in peripheral sites, such as limb sarcomas. In this setting direct signaling by the cytokine through the receptor induces tumor cell death (Aggarwal and Natarajan, 1996. Eur Cytokine Netw 7:93-124).

In immunological settings, agents that block TNF receptor signaling (e.g., anti-TNF mAb, soluble TNF-R fusion proteins) have been used to treat diseases like  
15 rheumatoid arthritis and inflammatory bowel disease. In these pathologies TNF acts to induce cell proliferation and effector function, thereby exacerbating autoimmune disease, and in this setting blocking TNF binding to its receptor(s) has therapeutic benefit (Beutler, 1999. J Rheumatol 26 Suppl 57:16-21).

A more recently discovered ligand/receptor system appears amenable to similar  
20 manipulations. Lymphotoxin beta (LT $\beta$ ), a TNF family member which forms heterotrimers with LT $\alpha$ , bind to the LT $\beta$ -R. Some adenocarcinoma tumor cells which express LT $\beta$ -R can be killed or differentiated when treated with an agonistic anti-LT $\beta$ -R mAb (Browning et al., 1996. J Exp Med 183: 867-878). In immunological settings it has been shown that anti- LT $\beta$  mAb or soluble LT $\beta$ -R-Ig fusion protein can block the  
25 development of inflammatory bowel diseases, possibly by influencing dendritic cell and T cell interaction (Mackay et al., 1998. Gastroenterology 115:1464-1475).

The TRAIL system also has potential as a cancer therapy. TRAIL interacts with a number of membrane bound and soluble receptors. Two of these receptors, TRAIL-R1 and TRAIL R2 (also called DR4 and DR5), transmit death inducing signals to  
30 tumor cells but not to normal cells, which express additional TRAIL receptors that do not induce death. These additional receptors are thought to function as decoys. The use of soluble TRAIL to kill tumor cells relies on the selective expression of decoy receptors on normal but tumor tissue (Gura, 1997. Science 277: 768).

Tumor cells themselves often express a variety of decoy receptors that block immune recognition or effector functions. Indeed some tumors overexpress TRAIL decoy receptors, apparently to avoid TRAIL mediated death (Sheikh et al., 1999. Oncogene 18: 4153-4159). This limits the utility of TRAIL as an anti-tumor agent in some settings. Similar observations have been made about a decoy receptor for FAS-L, which is overexpressed by lung and colon cancer cells (Pitti et al., 1998. Nature 396: 699-703), and for the IL-1 receptor antagonist (Mantovani et al., 1998. Ann. N Y Acad. Sci. 840: 338-351). Decoy receptors are also employed by viral genomes to protect infected host cells from host defense mechanisms.

10        APRIL (A Proliferation Inducing Ligand) is a new member of the TNF family of proteins. APRIL expression and functional studies suggest that this protein is utilized by tumor cells to induce rapid proliferation. Tumor cell lines treated with soluble APRIL protein or transfected with APRIL cDNA grow rapidly in vitro. APRIL transfected cells implanted into immunodeficient mice grow rapidly as tumors. Finally, 15 human tumor cells, but not normal tissue, express high levels of APRIL messenger RNA. These observations suggest that APRIL binds to a receptor that is also expressed by tumor cells, setting up autocrine or paracrine tumor cell activation. In addition, it is possible that APRIL acts in other disease settings, such that activating or blocking the APRIL pathway would have additional utility. For example, underexpression or 20 overexpression of APRIL may play a role in developmental defects, since development is often characterized by the carefully controlled balance between cell proliferation and cell death. Similarly, APRIL may act in cell proliferative diseases, such as those that occur in connection with some autoimmune diseases (e.g., lupus) or in inflammatory diseases where cell populations expand rapidly (e.g., bacterial sepsis).

25        Based on the known utility of using agonists and antagonists of TNF and TNF receptor family members as disease modifiers, the APRIL pathway presents itself as an important target for drug development. This is particularly true for cancer therapy since tumor cells appear to produce and utilize APRIL to support their own growth, and are therefore unlikely to produce decoy receptors or other antagonists of the APRIL 30 pathway. Thus the APRIL pathway is uniquely different from, for example, the TRAIL or FAS-L pathways, which can be thwarted by tumor decoy receptors.

Current treatments for cancer are inadequate for many tumor types, due to poor efficacy, low impact on survivorship, toxicity that causes severe side effects, or combinations thereof. Therefore there is a need to identify and develop additional

methods for treating cancer growth which can provide efficacy without inducing severe side effects. Antagonists of the APRIL pathway, including anti-APRIL mAbs, anti-APRIL receptor mAbs, soluble APRIL receptor-Ig fusion proteins, natural antagonists, small molecule antagonists, and chemical, pharmaceutical, or other antagonists would  
5 thus be useful.

To this end we have identified B cell mediated protein (BCM or BCMA) as a receptor for APRIL.

### SUMMARY OF THE INVENTION

10 Applicants have found that BCMA is a receptor for the tumor necrosis factor, APRIL. APRIL is the same molecule previously described in WO 99 12965, which is incorporated by reference herein. The APRIL receptor is referred to hereinafter as "APRIL-R". The present invention is directed to methods of treatment and pharmaceutical preparations for use in the treatment of mammalian species having or at  
15 risk of having cancer. Such subjects include subjects already afflicted with cancer, or which have already received cancer therapy.

The methods and compositions of this invention capitalize in part upon the discovery that certain agents that are cancer therapeutic agents, defined herein as APRIL-R antagonists, including for example, anti-APRIL-R antibodies, may be used in  
20 the treatment of subjects at risk of developing cancer as defined herein or the need for cancer treatment.

The cancer therapeutic agents of the invention may be administered by any route of administration which is compatible with the selected agent, and may be formulated with any pharmaceutically acceptable carrier appropriate to the route of  
25 administration. Preferred routes of administration are parenteral and, in particular, intravenous, intraperitoneal, and intracapsular. Treatments are also preferably conducted over an extended period on an outpatient basis. Daily dosages of the cancer therapeutic agents are expected to be in the range of about 0.01-1000  $\mu\text{g/kg}$  body weight, and more preferably about 10-300  $\mu\text{g/kg}$  body weight, although precise dosages  
30 will vary depending upon the particular cancer therapeutic agent employed and the particular subject's medical condition and history.

The treatments of the present invention are useful in eradicating a substantially clonal population (colony) of transformed cells from the body of a mammal, or to suppress or to attenuate the growth of the colony, which is most commonly referred to

as a tumor. As such they are useful in prolonging the lives, and in maintaining the quality of life, of subjects at risk of, or already afflicted with cancer.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleic acid sequence (SEQ ID NO:1) of a cDNA for murine APRIL and its derived amino acid sequence (SEQ ID NO:3) as mapped in vector pCCM213.10. Shown underlined is the myc epitope and the amino acids  
5 derived from FasL. The beginning of APRIL extracellular domain coding sequence is indicated by arrows.

Figure 2 shows the nucleic acid sequence (SEQ ID NO: 4) and its derived amino acid sequence (SEQ ID NO:6) of FLAG-human APRIL construct for expression in mammalian cells. The map indicates the signal sequence (1-15); the FLAG epitope  
10 (AA 16-23) and the beginning of human APRIL extracellular domain coding sequence (32-end).

Figure 3A shows the nucleic acid sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8) of full length human BCMA. Figure 3B shows the nucleic acid sequence (SEQ ID NO:11) of pJST538, a plasmid encoding a human APRIL-R-  
15 hIgGFc fusion construct and its derived amino acid sequence (SEQ ID NO:12).

Figure 4 shows binding of myc-murine APRIL to the murine B cell lymphoma line A20. 3 separate experiments show specific binding of APRIL to A20 cells compared to A) unstained cells and cells stained with R1532 only, B) cells stained with RANKL-L and R1532 and C) cells stained with APRIL and an irrelevant rabbit sera.

20 Figure 5 shows binding of myc-murine APRIL to the human B cell lymphoma line RAJI. 2 separate experiments show specific binding of APRIL to RAJI cells compared to A) unstained cells and cells stained with R1532 only, and cells stained with RANKL-L and R1532 and B) cells stained with APRIL and an irrelevant rabbit sera

Figure 6 shows that APRIL binding to A20 cells (A) and Raji cells (B) is  
25 competed using soluble BAFF protein or soluble BCMA-Ig protein.

Figure 7 shows binding of FLAG-human APRIL to various cell lines: A) A20 cells, B) HT29 cells, C)NIH3T3 cells. Specific binding is demonstrated using biotinylated anti-FLAG mAb M2 detection compared to binding seen with an irrelevant isotype control mAb or without addition of FLAG-APRIL.

30 Figure 8 shows immunoprecipitation of myc-mApril using BCMA-Fc fusion protein. Upper left panel show specific hBMCA-Fc/myc-mAPRIL and positive control OPG-Fc/Rank-1 immunoprecipitations, compared to upper right negative controls. Lower panels demonstrate that the amounts of protein loaded were equivalent.



Figure 9 shows an ELISA format experiments demonstrating that FLAG-hAPRIL binds to hBCMA-fc fusion protein. Various receptor-Fc fusion proteins were coated onto the ELISA plates and bound with FLAG-tagged ligands. A) Detection of the bound ligands revealed that only APRIL and hBAFF specifically bind to hBCMA-Fc, but not hCD40-Fc. B) Dose titration showing that the ELISA signal detected after binding hAPRIL or hBAFF onto hBCMA-Fc coated plates is linearly dependent on the amount of protein added.

Figure 10 show an immunoprecipitation of FLAG-hAPRIL and FLAG-hBAFF by hBMCA-Fc fusion protein. Upper 4 panels show the equivalence of the protein loads in each immunoprecipitation, while the lower panels show that hAPRIL and hBAFF are immunoprecipitated by hBCMA-Fc but not hTRAIN-Fc.

Figure 11 show the BiaCore analysis of the binding of myc-mAPRIL, FLAG-hBAFF, and FLAG-mBAFF to hBMCA, hLTbeta receptor, or hTNF-R80 or blank showing specific binding only to hBCMA.

Figure 12 shows APRIL binding to BCMA transfected cells. 293EBNA cells were transfected with a plasmid that expresses full length hBCMA. Cells were harvested 48 hours later using 5mM EDTA and stained with myc-nAPRIL. Panel A shows that the extent of staining is dose dependent. Panel B shows that the staining decreased to background level using a soluble BCMA-Ig protein.

Figure 13 shows the growth of NIH3T3 cells implanted subcutaneously in immunodeficient (Nu/Nu) mice treated with control reagents or with BCMA-Ig fusion protein. In this model the NIH3T3 cells form a fibrosarcoma.

Figure 14 shows the growth of the human colon carcinoma SW480 implanted subcutaneously in immunodeficient (Nu/Nu) mice treated with control reagents or with hBCMA-Ig fusion protein.

Figure 15A shows the growth of the human colon carcinoma HT29 implanted subcutaneously in immunodeficient (Nu/Nu) mice treated with control reagents or with hBCMA-Ig fusion protein. Figure 15B shows the growth of the human lung carcinoma A549 implanted subcutaneously in immunodeficient (Nu/Nu) mice treated with control reagents or with hBCMA-Ig fusion protein

## DETAILED DESCRIPTION

### Definitions

In order to more clearly and concisely point out the subject matter of the claimed invention, the following definitions are provided for specific terms used in the following written description and appended claims.

The invention will now be described with reference to the following detailed description of which the following definitions are included:

The terms "APRIL receptor" or "APRIL-R" when used herein encompass native sequence APRIL-R and APRIL-R variants. The APRIL-R may be isolated from a variety of sources, such as from murine or human tissue types or from another source, or prepared by recombinant or synthetic methods. The term APRIL-R further refers to a polypeptide which is capable of binding to the tumor necrosis family member, APRIL, or to homologs or fragments thereof. An example of an APRIL-R is BCMA.

The term "BCMA" or "BCM" refers to the novel protein for B cell maturation as described in Gras et al. (1995), International Immunology, 7: 1093-1106, "BCMAp: an integral membrane protein in the golgi apparatus of human mature B lymphocytes"; Y. Laabi et al. (1992), EMBO J., 11, 3897-3904, "A new gene BCM on Chromosome 16 is fused to the interleukin 2 gene by a t(4;16) (q26;p13) translocation in a malignant T cell lymphoma".

A "native sequence APRIL-R" comprises a polypeptide having the same amino acid sequence as APRIL-R derived from nature. Such native sequence APRIL-R can be isolated from nature or can be produced by recombinant or synthetic means. The native sequence APRIL-R can be naturally-occurring truncated or secreted forms of the APRIL-R (e.g. soluble forms containing for instance, an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the APRIL-R. In one embodiment of the invention, the native sequence APRIL-R is a mature or full-length native sequence APRIL-R polypeptide comprising amino acids 1 to 184 of SEQ ID NO: 8 or fragment thereof.

The "APRIL-R extracellular domain" or "APRIL-R ECD" refers to a form of APRIL-R which is essentially free of transmembrane and cytoplasmic domains of APRIL-R. Ordinarily, APRIL-R extracellular domain will have less than 1% of such transmembrane and cytoplasmic domains and will preferably have less than 0.5% of such domains. Optionally, APRIL-R ECD will comprise amino acid residues 1 to 51,

or 1 to 52, or 1 to 53 of SEQ ID NO: 8. In a preferred embodiment, the APRIL-ECD comprises amino acid residues 4 to 51 of SEQ ID NO: 8 or more preferably amino acid residues 8 to 41 of SEQ ID NO:8. It will be understood by the skilled artisan that the transmembrane domain identified for the APRIL-R polypeptide of the present invention is identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain specifically mentioned herein.

“APRIL-R variant” means an active APRIL-R as defined below having at least about 80% amino acid sequence identity with the APRIL-R having the deduced amino acid sequence shown in SEQ ID NO:5 for a full-length native sequence APRIL-R or with a APRIL-R ECD sequence. Such APRIL-R variants include, for instance, APRIL-R polypeptides wherein one or more amino acid residues are added, or deleted, at the end or C-terminus of the sequence of SEQ ID NO:8. Ordinarily, a APRIL-R variant will have at least about 80% or 85% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity, and even more preferably at least about 95% amino acid sequence identity with the amino acid sequence of SEQ ID NO:8.

“Percent (%) amino acid sequence identity” with respect to APRIL-R sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the APRIL-R sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publically available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared.

The term “epitope tagged” when used herein refers to a chimeric polypeptide comprising APRIL-R, or a domain sequence thereof, fused to a “tag polypeptide”. The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, or which can be identified by some other agent, yet is short enough such that it does not interfere with activity of the APRIL-R. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross - react with other

epitopes. Suitable tag polypeptides generally have at least 6 amino acid residues and usually between about 8 to about 50 amino acid residues (preferably, about 10 to about 20 residues).

“Isolated” when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminate components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non- proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the APRIL-R’s natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

The term “antibody” is used in the broadest sense and specifically covers single APRIL-R monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies) and anti- APRIL-R antibody compositions with polypepitopic specificity. The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

A “purified preparation” or a “substantially pure preparation” of a polypeptide, as used herein, means a polypeptide that has been separated from other proteins, lipids, and nucleic acids with which it naturally occurs. Preferably, the polypeptide is also separated from other substances, e.g., antibodies, matrices, etc., which are used to purify it.

The terms, “treating”, “treatment” and “therapy” as used herein refers to curative therapy, prophylactic therapy, and preventative therapy.

The terms “peptides”, “proteins”, and “polypeptides” are used interchangeably herein.

“Biologically active” as used herein, means having an *in vivo* or *in vitro* activity which may be performed directly or indirectly. Biologically active fragments of

APRIL-R may have, for example, 70% amino acid homology with the active site of the receptor, more preferably at least 80%, and most preferably, at least 90% homology.

Identity or homology with respect to the receptor is defined herein as the percentage of amino acid residues in the candidate sequence which are identical to the APRIL-R

5 residues in SEQ ID NO:8.

The term "mammal" as used herein refers to any animal classified as a mammal including humans, cows, horses, dogs, mice and cats. In preferred embodiment of the invention, the mammal is a human.

The practice of the present invention will employ, unless otherwise indicated,  
10 conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are described in the literature.

Reference will now be made in detail to the present preferred embodiments of the invention. This invention relates to the use of APRIL-R and APRIL-R related  
15 molecules to effect the growth and maturation of B-cells and non-B cells, specifically as they relate to tumor cells. The invention also relates to the use of APRIL-R and APRIL-R related molecules to effect responses of the immune system, as necessitated by immune-related disorders. Additionally, this invention encompasses the treatment of cancer and immune disorders through the use of a APRIL-R, or APRIL-R related  
20 gene through gene therapy methods.

The APRIL-R and homologs thereof produced by hosts transformed with the sequences of the invention, as well as native APRIL-R purified by the processes known in the art, or produced from known amino acid sequences, are useful in a variety of methods for anticancer, antitumor and immunoregulatory applications. They are also  
25 useful in therapy and methods directed to other diseases.

Another aspect of the invention relates to the use of the polypeptide encoded by the isolated nucleic acid encoding the APRIL-R in "antisense" therapy. As used herein, "antisense" therapy refers to administration or *in situ* generation of oligonucleotides or their derivatives which specifically hybridize under cellular conditions with the cellular  
30 mRNA and/or DNA encoding the ligand of interest, so as to inhibit expression of the encoded protein, i.e. by inhibiting transcription and/or translation. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix.

In general, "antisense" therapy refers to a range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.

An antisense construct of the present invention can be delivered, for example, as an expression plasmid, which, when transcribed in the cell, produces RNA which is complementary to at least a portion of the cellular mRNA which encodes Kay-ligand. Alternatively, the antisense construct can be an oligonucleotide probe which is generated ex vivo. Such oligonucleotide probes are preferably modified oligonucleotides which are resistant to endogenous nucleases, and are therefore stable in vivo. Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidates, phosphothioate and methylphosphonate analogs of DNA (See, e.g., 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy have been reviewed, for example, by Van Der Krol et al., (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48: 2659-2668, specifically incorporated herein by reference.

The APRIL-R of the invention, as discussed above, is a member of the TNF receptor family. The protein, fragments or homologs thereof may have wide therapeutic and diagnostic applications.

The polypeptides of the invention specifically interact with APRIL, a polypeptide previously described in WO99/12964 incorporated by reference herein. However, the peptides and methods disclosed herein enable the identification of molecules which specifically interact with the APRIL-R or fragments thereof.

The claimed invention in certain embodiments includes methods of using peptides derived from APRIL-R which have the ability to bind to APRIL. Fragments of the APRIL-R's can be produced in several ways, e.g., recombinantly, by PCR, proteolytic digestion or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end or both ends of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments.

Polypeptide fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-moc or t-boc chemistry. For example, peptides and DNA sequences of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragment, or divided

into overlapping fragments of a desired length. Methods such as these are described in more detail below.

#### Generation of Soluble Forms of APRIL-R

Soluble forms of the APRIL-R can often signal effectively and hence can be administered as a drug which now mimics the natural membrane form. It is possible that the APRIL-R claimed herein are naturally secreted as soluble cytokines, however, if not, one can reengineer the gene to force secretion. To create a soluble secreted form of APRIL-R, one would remove at the DNA level the N-terminus transmembrane regions, and some portion of the stalk region, and replace them with a type I leader or alternatively a type II leader sequence that will allow efficient proteolytic cleavage in the chosen expression system. A skilled artisan could vary the amount of the stalk region retained in the secretion expression construct to optimize both ligand binding properties and secretion efficiency. For example, the constructs containing all possible stalk lengths, i.e. N-terminal truncations, could be prepared such that proteins starting at amino acids 1 to 52 would result. The optimal length stalk sequence would result from this type of analysis.

#### Generation of Antibodies Reactive with the APRIL-R

The invention also includes antibodies specifically reactive with the claimed APRIL-R or its co-receptors. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers, or other techniques, well known in the art.

An immunogenic portion of APRIL-R or its co-receptors can be administered in the presence of an adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

In a preferred embodiment, the subject antibodies are immunospecific for antigenic determinants of APRIL-R or its co-receptors, e.g. antigenic determinants of a polypeptide of SEQ ID NO:8, or a closely related human or non-human mammalian homolog (e.g. 70, 80 or 90 percent homologous, more preferably at least 95 percent homologous). In yet a further preferred embodiment of the present invention, the anti-

APRIL-R or anti-APRIL-co-receptor antibodies do not substantially cross react (i.e. react specifically) with a protein which is e.g., less than 80 percent homologous to SEQ ID NO:8; preferably less than 90 percent homologous with SEQ ID NO:8; and, most preferably less than 95 percent homologous with SEQ ID NO:8. By "not substantially cross react", it is meant that the antibody has a binding affinity for a non-homologous protein which is less than 10 percent, more preferably less than 5 percent, and even more preferably less than 1 percent, of the binding affinity for a protein of SEQ ID NO.8.

The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with APRIL-R, or its receptors. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example,  $F(ab)_2$  fragments can be generated by treating antibody with pepsin. The resulting  $F(ab)_2$  fragment can be treated to reduce disulfide bridges to produce Fab' fragments. The antibodies of the present invention are further intended to include biospecific and chimeric molecules having anti-APRIL-R or anti-APRIL-co-receptor activity. Thus, both monoclonal and polyclonal antibodies (Ab) directed against APRIL-R, and their co-receptors, and antibody fragments such as Fab' and  $F(ab')_2$ , can be used to block the action of the APRIL-R and its respective co-receptors.

Various forms of antibodies can also be made using standard recombinant DNA techniques. (Winter and Milstein, Nature 349: 293-299 (1991) specifically incorporated by reference herein.) For example, chimeric antibodies can be constructed in which the antigen binding domain from an animal antibody is linked to a human constant domain (e.g. Cabilly et al., U.S. 4,816,567, incorporated herein by reference). Chimeric antibodies may reduce the observed immunogenic responses elicited by animal antibodies when used in human clinical treatments.

In addition, recombinant "humanized antibodies" which recognize APRIL-R or its co-receptors can be synthesized. Humanized antibodies are chimeras comprising mostly human IgG sequences into which the regions responsible for specific antigen-binding have been inserted. Animals are immunized with the desired antigen, the corresponding antibodies are isolated, and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies



minimize the use of heterologous (i.e. inter species) sequences in human antibodies, and thus are less likely to elicit immune responses in the treated subject.

Construction of different classes of recombinant antibodies can also be accomplished by making chimeric or humanized antibodies comprising variable domains and human constant domains (CH1, CH2, CH3) isolated from different classes of immunoglobulins. For example, antibodies with increased antigen binding site valencies can be recombinantly produced by cloning the antigen binding site into vectors carrying the human : chain constant regions. (Arulanandam et al., J. Exp. Med., 177: 1439-1450 (1993), incorporated herein by reference.)

In addition, standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites. The antigen binding affinity of a humanized antibody can be increased by mutagenesis based on molecular modeling. (Queen et al., Proc. Natl. Acad. Sci. 86: 10029-33 (1989)) incorporated herein by reference.

#### Generation of Analogs: Production of Altered DNA and Peptide Sequences

Analogs of the APRIL-R can differ from the naturally occurring APRIL-R in amino acid sequence, or in ways that do not involve sequence, or both. Non-sequence modifications include in vivo or in vitro chemical derivatization of the APRIL-R. Non-sequence modifications include, but are not limited to, changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation.

Preferred analogs include APRIL-R biologically active fragments thereof, whose sequences differ from the sequence given in SEQ ID NO:8, by one or more conservative amino acid substitutions, or by one or more non-conservative amino acid substitutions, deletions or insertions which do not abolish the activity of APRIL-ligand. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g. substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and, phenylalanine, tyrosine.

#### Uses

The full length APRIL-R gene (SEQ ID NO:8) or portions thereof may be used as hybridization probes for a cDNA library to isolate, for instance, still other genes which have a desired sequence identity to the APRIL-R sequence disclosed in SEQ ID

NO: 6. Nucleotide sequences encoding APRIL-R can also be used to construct hybridization probes for mapping the gene which encodes the APRIL-R and for the genetic analysis of individuals with genetic disorders. Screening assays can be designed to find lead compounds that mimic the biological activity of a APRIL-R.

5 Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. Nucleic acids which encode APRIL-R or its modified forms can also be used to generate either transgenic animals or "knock out" animals which in turn are

10 useful in the development and screening of therapeutically useful reagents, including for example cancer reagents.

The APRIL-R and homologs thereof produced by hosts transformed with the sequences of the invention, as well as native APRIL-R purified by the processes known in the art, or produced from known amino acid sequences, are useful in a variety of

15 methods for anticancer applications.

In one embodiment of the invention is a method of treating a mammal for a condition associated with undesired cell proliferation by administering to the mammal a therapeutically effective amount of a composition comprising an APRIL-R antagonist, wherein the APRIL-R antagonist comprises a polypeptide that antagonizes the

20 interaction between APRIL and its cognate receptor or receptors, with a pharmaceutically acceptable recipient.

In a preferred embodiment the cognate receptor of APRIL on the surface of the cell is BCMA.

The method can be used with any APRIL-R antagonist that has a polypeptide

25 that antagonizes the interaction between APRIL and its cognate receptor or receptors. Examples of APRIL-R antagonists include but are not limited to soluble APRIL-R polypeptide, including but not limited to soluble BCMA; soluble chimeric APRIL-R molecules, including but not limited to BCMA-IgG-Fc and anti-APRIL-R antibody homologs, including but not limited to anti-BCMA monoclonal antibody.

30 The method of the invention can be used with any condition associated with undesired cell proliferation. In particular the methods of the present invention can be used to treat tumor cells which express APRIL and /or APRIL-R (i.e. BCMA).

Examples of cancers whose cell proliferation is modulated by APRIL may be screened by measuring in vitro the level of APRIL and /or APRIL-R (i.e. BCMA)

message expressed in tumor tissue libraries. Tumor tissue libraries in which APRIL and /or APRIL-R (i.e. BCMA) message is highly expressed would be candidates.

Alternatively, one may screen for candidates searching the public and private databases (i.e. Incyte data base) with, for example, the full length human APRIL cDNA sequence.

- 5 Applying these techniques, it was found, for example, that APRIL mRNA expression was detected in a large number of tumor types, including but not limited to those found in Table 1 below:

TABLE 1

<u>Library Description</u>
Prostate tumor line, LNCaP, CA, 50M, untreated, TIGR
T-lymphocyte tumor, lymphoma, TIGR
Ovary tumor, papillary serous cystadenocarcinoma
Lung, metastatic/adrenocarcinoma, COPD, 47M
Breast tumor, adenocarcinoma, 46F, SUB, metastatic/BRSTNOT33
Ganglion, dorsal root, cervical, metastatic/lymphoma, 32M, NORM
Brain tumor, frontal, neuronal neoplasm, 32M
Prostate tumor, adenocarcinoma, 59M, SUB, metastatic/PROSNOST19
Colon tumor, hepatic flexure, adenocarcinoma, 55M, SUB, metastatic/COLATMT01
Pancreatic tumor, TIGR
Paraganglion tumor, paraganglioma, metastatic/renal cell carcinoma, 46M
Breast, metastatic/ductal carcinoma, 43F, metastatic/BRSTTUT16

Kidney tumor, renal cell CA, 51F
Bladder, mw/TC CA, CA in situ, 60M, m/BLADTUT04
Uterus tumor, endometrial, F, TIGR
Prostate, BPH, mw/adenocA, PIN, 59M
Lung, mw/adenocA, 53M, m/LUNGTUT17
Bone tumor/line, MG-63, osteoSAR/giant cell, M/F, pool, RP
Brain, frontal cortex, aw/lung CA, 77M
Colon tumor, adenocA, NORM, SUB, CGAP
Lung tumor, squamous cell CA, 57M
Lung, mw/adenocA, 63M
Prostate, AH, mw/adenocA, 50M, m/PROSTUT01
Periph blood, B-lymphocytes, CLL, pool, NORM, 3' CGAP
Colon tumor, adenocA, pool, NORM, 3'/5' CGAP
Kidney, mw/renal cell CA, 8,53F, pool, NORM
Ovary, dermoid cyst, 22F
Colon tumor, adenocA, NORM, 3' CGAP

Colon tumor, adenoCA, 3', CGAP
Prostate, BPH, mw/adenoCA, 70M, SUB
Ovary tumor, mets colon adenoCA, 58F
Uterus, myometrium, mw/leiomyoma, 43F
Sm intestine, ileum, mw/CUC, 25F
Lymph node, peripancreatic, aw/pancreatic adenoCA, 65M
Ovary, aw/leiomyomata, 36F, NORM
Lung, mw/spindle cell carcinoid, 62F
Lung tumor, squamous CA, 50M
Brain tumor, meningioma, 36M
Tumor, adenoCA, 65F, m/PANCNOT08
Lung, mw/endobronchial carcinoid, 33M
Adrenal gland, mw/pheochromocytoma, 43F, m/ADRETUT07
Brain tumor, frontal, meningioma, 50M
Kidney tumor, clear cell type cancer, pool, NORM, 3' CGAP
Breast, mw/lobular CA, 67F
Lung, mw/mets osteoSAR, aw/pleura mets, 58M, NORM

Prostate tumor, adenoCA, 59M, SUB, m/PROSNOT19
Sm intestine tumor, ileum, mets endometrial adenoCA, 64F
Ovary tumor, adenoCA, 58F
Breast, NF breast disease, 46F
Brain tumor, frontal, mets hypernephroma, 58M
Kidney tumor, Wilms', pool, WM/WN
Lung, mw/mets thyroid CA, 79M, m/LUNGTUT02
Lung tumor, mets thyroid CA, 79M, m/LUNGNOT03
Parathyroid tumor, adenoma, M/F, NORM, WM
Pancreatic tumor, anaplastic CA, 45F
Ovary, mw/mucinous cystadenoCA, 43F, m/OVARTUT01
Lung tumor, squamous cell CA, pooled, NORM, CGAP
Breast tumor, adenoCA, 46F, m/BRSTNOT17
Uterus, mw/leiomyoma, aw/colon adenoCA, 45F
Lung, mw/adenoCA, aw/node, diaphragm mets, 63F
Breast tumor, adenoCA, 46F, m/BRSTNOT33

Prostate tumor, adenoCA, 66M, m/PROSNOT15, PROSDIN01
Breast tumor, adenoCA, 54F, m/BRSTNOT03
Germ cell tumor, pool, SUB, 3' CGAP
Bone marrow, tibia, aw/mets alveolar rhabdomyoSAR, 16M
Prostate, AH, mw/adenoCA, 57M, m/PROSTUT04
Breast, PF changes, mw/adenoCA, 55F, m/BRSTTUT01
Uterus tumor, serous papillary CA, F, pooled, 3' CGAP
Ovary tumor, mucinous cystadenoCA, 43F, m/OVARNOT03
Breast, PF changes, mw/adenoCA, intraductal CA, 43F
Breast, mw/ductal CA, CA in situ, aw/node mets, 62F
Neuroganglion tumor, ganglioneuroma, 9M
Pancreas tumor, adenoCA, 3' CGAP
Uterus tumor, endometrial adenoCA, F, pooled, 3' CGAP
Lung tumor, neuroendocrine carcinoid, pool, NORM, 3' CGAP

The APRIL-R antagonists of the subject invention which are used in treating conditions associated with undesired cell proliferation, in particular tumor therapy, advantageously inhibit tumor cell growth greater than 10%, 20%, 30% or 40% and most advantageously greater than 50%. The APRIL-R antagonists are obtained through screening (see, for example, the discussion in Example 6). For example, APRIL-R

antagonists can be selected on the basis of growth inhibiting activity (i.e. greater than 10%, 20%, 30%, 40% or 50%) against the human colon carcinoma HT29 or human lung carcinoma A549 (see, for example, the discussion in Figure 15) which are derived from a colon and lung tumor respectively.

5           Another embodiment of the invention, provides methods of inhibiting B-cell and non-B cell growth, dendritic cell-induced B-cell growth and maturation or immunoglobulin production in an animal using APRIL-R polypeptide.

10           In another embodiment, the invention provides methods of using APRIL-R in the treatment of autoimmune diseases, hypertension, cardiovascular disorders, renal disorders, B-cell lympho-proliferate disorders, immunosuppressive diseases, organ transplantation, inflammation, and HIV. Also included are methods of using agents for treating, suppressing or altering an immune response involving a signaling pathway between APRIL-R and its ligand.

15           The present invention also provides pharmaceutical compositions comprising a APRIL-R polypeptide and a pharmaceutically acceptable excipient. Suitable carriers for a APRIL-R polypeptide, for instance, and their formulations, are described in Remington' Pharmaceutical Sciences, 16<sup>th</sup> ed., 1980, Mack Publishing Co., edited by Oslo et al. Typically an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic. Examples of the carrier  
20           include buffers such as saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7.4 to about 7.8. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers, which matrices are in the form of shaped articles, e.g. liposomes, films or microparticles. It will be apparent to those  
25           of skill in the art that certain carriers may be more preferable depending upon for instance the route of administration and concentration of the a APRIL-R polypeptide being administered.

30           Administration may be accomplished by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular) or by other methods such as infusion that ensure delivery to the bloodstream in an effective form.

          Practice of the present invention will employ, unless indicated otherwise, conventional techniques of cell biology, cell culture, molecular biology, microbiology, recombinant DNA, protein chemistry, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, **Molecular**



- Cloning: A Laboratory Manual**, 2nd edition. (Sambrook, Fritsch and Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989; **DNA Cloning**, Volumes I and II (D.N. Glover, ed), 1985; **Oligonucleotide Synthesis**, (M.J. Gait, ed.), 1984; U.S. Patent No. 4,683,195 (Mullis et al.); **Nucleic Acid Hybridization** (B.D. Hames and S.J. Higgins, eds.), 1984; Transcription and Translation (B.D. Hames and S.J. Higgins, eds.), 1984; **Culture of Animal Cells** (R.I. Freshney, ed). Alan R. Liss, Inc., 1987; **Immobilized Cells and Enzymes**, IRL Press, 1986; **A Practical Guide to Molecular Cloning** (B. Perbal), 1984; **Methods in Enzymology**, Volumes 154 and 155 (Wu et al., eds), Academic Press, New York; **Gene Transfer Vectors for Mammalian Cells** (J.H. Miller and M.P. Calos, eds.), 1987, Cold Spring Harbor Laboratory; **Immunochemical Methods in Cell and Molecular Biology** (Mayer and Walker, eds.), Academic Press, London, 1987; **Handbook of Experiment Immunology**, Volumes I-IV (D.M. Weir and C.C. Blackwell, eds.), 1986; **Manipulating the Mouse Embryo**, Cold Spring Harbor Laboratory Press, 1986.

The following Examples are provided to illustrate the present invention, and should not be construed as limiting thereof.

#### EXAMPLES:

The following methods were used in the Examples disclosed hereinafter.

##### 5   **Methods:**

##### **Cloning and expression of myc-tagged murine APRIL (CCM776) in *Pichia pastoris*.**

The expression vector pCCM213.10 was constructed by taking PDR004 (H98 muAPRIL with superFAS-ligand stalk attached to N terminus along with FLAG  
10   epitope tag) and excising out the mu APRIL coding sequence from Sac I to NotI. Synthetic oligonucleotides LTB-559 and 560 form a Xho-I-SacI linker which contain an alpha mating factor leader sequence, myc epitope tag, as well as the KEL motif from FAS ligand. Both the muAPRIL fragment and linker were ligated into the Xho-I-NotI sites of pccm211, a *Pichia pastoris* expression plasmid.

15       PCCM213.10 was linearized with StuI, electroporated into GS115 strain (his4-) and plated into minimal media containing dextrose. HIS4 transformants were analyzed for protein expression by inoculating a single representative colony in rich media (BMGY: Buffered glycerol complex medium) and allowing it to grow to density for 48 hours at 30C. Cultures were spun, and cell pellets were resuspended (1:5) in a rich  
20   induction media containing 1.5% methanol (BMMY:Buffered methanol complex media). After two days of induction at 30C, supernatants were run out on SDS-PAGE and assessed for the presence of muAPRIL. Coomassie staining and Western blot (with the anti-myc mAb 9E10) showed that one strain, CCM776, produced adequate amounts of the glycosylated form myc-tagged-H98 muAPRIL protein.

##### 25   **Myc-mAPRIL purification**

Myc-mApril, a protein of 149 amino acids was expressed in *pichia*. This protein has an isoelectric point of 7.45. 175 ml of *pichia* supernatant was dialyzed and buffer exchanged to to 10mM Tris pH 6.8 overnight and then passed through a 20 ml SP column. The column was washed extensively with 10mM Tris-HCl, pH 6.8, and  
30   eluted with 250mM NaCl in PBS. A second step purification was achieved using a gel filtration column (S300). Fractions containing myc-April from 20 ml SP column were concentrated by centrifugation to a volume of 7 ml. After gel filtration, we recovered 8 mg of myc-APRIL as detected by OD and coomassie gel. We also performed Western blot analysis using mouse monoclonal 9E10 antibody (anti-myc)

showing that the myc tag is intact after the purification steps. N terminal sequence verified that the purified protein corresponds to myc-mApril.

#### **FLAG-human April purification.**

Plasmid ps429 (subsequently named p1448) was used to transiently transfect  
5 293 T cells using lipofectamine reagent (Gibco-Brl) and serum free media. The plasmid, constructed in the mammalian expression vector PCR3 (Invitrogen) encodes the receptor-binding domain of human APRIL, with an N-terminal protein into the cell culture media. FLAG-APRIL protein was purified from serum free media using an anti-FLAG mAb M2 column and excess purified FLAG peptide, following the  
10 manufacturers' instructions (Kodak).

#### **HBMCA-Fc purification.**

HBMCA-Fc was transiently transfected into 293 cells. Conditioned media from 293 cells over-expressing hBCM-Fc was loaded into a protein A column. Protein was eluted using 25 mM phosphate 100mM NaCl pH 2.8 followed by neutralization with  
15 1/20 volume of 0.5 M NaPO<sub>4</sub> pH 8.6. Selected fractions based in OD 280 were subject to reducing and non-reducing SDS-PAGE gels and western blots to identify the purified protein. 3 mg of protein were recovered from 500 ml of conditioned media.

#### **Myc-mAPRIL binds to various cell lines in FACS analysis.**

450 ng/ml of purified myc-mAPRIL was bound to cell lines in 100ul  
20 PBS/2%FBS + Fc blocking reagents (FcBlock @ 20ug/ml (Pharmingen) and purified human IgG @ 10 ug/ml (Sandoz) on ice for 1 hour. Positive binding was revealed using specific rabbit anti-murine APRIL antisera (1:500) and donkey anti-rabbit IgG-FITC (Jackson). Cell lines A20, Raji, NIH3T3, and HT29 were maintained in media as suggested by the supplier (ATCC Bethesda, MD). BJAB cells were cultured in  
25 HEPES-buffered RPMI supplemented with 10% FBS and L-glutamine. In competition assays 450ng/ml myc-murine APRIL was added with 1 ug/ml of competitor protein.

#### **Example 1: Detection of APRIL binding to APRIL-R using a Plate Assay**

In this example, BCMA Association with April was tested.

In order to test whether BCMA associates with April we performed a co-  
30 immunoprecipitation experiment. Both soluble proteins hBCMA-Fc and myc-mApril were used in this experiment.

HBCMA-Fc and LTbR-Fc were added with different TNF ligands: myc-mApril; myc-CD40L and myc-RANKL into media containing 10% FBS for ½ hour at room temperature. Fc proteins were bound to protein A beads for 1-2 hours, washed

three times with 1 ml of PBS, analyzed by immunoblotting with mouse monoclonal 9E10 (anti-myc) antibody and developed using enhanced chemiluminescence.

We detected myc-APRIL in hBCMA-Fc immunoprecipitates indicating that BCMA interacts with April in a specific way since other TNF ligands, myc-CD40L and myc-RANKL did not have the ability to bind to BCMA. Myc-April does not associate with LTbR-Fc.

The same membrane was stripped and reblotted with anti-hIG-HRP to show that the same amount of LTbR-Fc with BCMA-Fc were used in the immunoprecipitates.

#### **Example 2:**

This example describes that hBCMA-FC interacts with FLAG-hAPRIL.

ELISA analysis: Coated plates with receptor-Fc fusion proteins (hBCMA-Fc-739 or hTNFR2-Fc-492) at 1 ug/ml in carbonate pH 9.6, overnight, 4C. Blocked for 2 hours at room temperature using PBS/5% non fat dry milk/0.5% Tween-20. 2x serial dilution of ligands were made in 100 ul of blocking buffer (TNFa-197 from 1000ng/ml, muBAFF-657 from 1000ng/ml, hApril-507 from 2000 ng/ml (inactive), hApril-429 from 5x concentrated media). After incubation with ligands the plate was washed in PBS) .5% Tween-20 and probed with 0.5ug/ml anti-FLAG mAb M2 in dilution buffer. The antibody was then detected using anti-mouse-PO 1/2000 with enzymatic development (OPD).

Immunoprecipitation experiments: 293T cells were transfected with indicated expression plasmid (Rec-Fc or flag ligand) in 9 cm plate. Transfected cells were left for 5d in 8ml Optimem media (Gibco-BRL). Immunoprecipitation were performed by mixing 200 ul of each receptor-conditioned media with 200 ul of each ligand-conditioned media + 400 ul PBS + 10 ul ProtG-Sepharose. These were rotated 1h on a wheel, washed 4x with 1ml PBS, then boiled in 50 ul sample buffer (+DTT). 20 ul of each immunoprecipitation was loaded per lane. Reveal blotting was done with 1ug/ml anti-FLAG M2 mAb (Sigma, St Louis MO) and anti-mouse PO (1/2000). A reprobe blot with anti-human-PO was also checked: 100 ul conditioned media was precipitated with MeOH/CHCl3/lysozyme. This mix was boiled in 50ul sample buffer (+DTT) and 20 ul was loaded. A Reveal blot was performed with anti-FLAG mAb M2 (1ug/ml) and anti-mouse-PO (1/2000).

#### **Example 3:**

This example describes the binding of myc-mAPRIL; hKayL-440 (hBAFF); and Flag-mBAFF to hBCMA-Ig, hLT-R-Ig, or hp80 TNFR-Ig. All experiments were performed at 25C with a 10 ul/ml minute flow rate.

Each experiment was performed using HBS buffer (10mM HEPES, 150 mM NaCl, 0.005% P20 surfactant, at pH 7.4). The same solution was used both as running  
5 buffer and as sample diluent.

The CM5 chip (BIAcore, Inc.) surface was first activated with N-hydroxysuccinimide/N-ethyl-N'-(3-diethylaminopropyl)-carbodiimide hydrochloride (BIAcore). Twenty ul of hBCMA-Ig; fifteen ul of hLT-R05-Ig and 10 ul of hp80-  
10 TNFR, diluted to 30g/ml in 10 mM acetic acid were then blocked with once with 30 ul and again with 15 ul of ethanolamine-HCL (pH 8.5). This resulted in a surface density of 1600-3700 resonance units (RU). The chip was regenerated with 20 ul of 1mM formic acid. These rejections were repeated five times to establish a reproducible and stable baseline.

15 For the experiment, 100 ul of myc-mApril, hKayL-440, and FLAG-mBAFF each was diluted to 30 ug/ml in diluent buffers and was injected over the surface of the chip. Immediately after each injection, the chip was washed with 500 ul of the diluent buffer. The surface was regenerated between experiments by injecting 20 ul of 1 mM formic acid; followed with another 15 ul injection formic acid. After regeneration, the  
20 chip was equilibrated with the dilution buffer.

#### **Example 4: Generation of Soluble Receptor Forms:**

To form a receptor inhibitor for use in humans, one requires the human receptor cDNA sequence of the extracellular domain. If the mouse form is known, human cDNA libraries can be easily screened using the mouse cDNA sequence and such  
25 manipulations are routinely carried out in this area. With a human cDNA sequence, one can design oligonucleotide primers to PCR amplify the extracellular domain of the receptor in the absence of the transmembrane and intracellular domains. Typically, one includes most of the amino acids between the last disulfide linked "TNF domain" and the transmembrane domain. One could vary the amount of "stalk" region included to  
30 optimize the potency of the resultant soluble receptor. This amplified piece would be engineered to include suitable restriction sites to allow cloning into various C-terminal Ig fusion chimera vectors. Alternatively, one could insert a stop signal at the 3' end and make a soluble form of the receptor without resorting to the use of a Ig fusion chimera approach. The resultant vectors can be expressed in most systems used in

biotechnology including yeast, insect cells, bacteria and mammalian cells and examples exist for all types of expression. Various human Fc domains can be attached to optimize or eliminate FcR and complement interactions as desired. Alternatively, mutated forms of these Fc domains can be used to selectively remove FcR or  
5 complement interactions or the attachment of N-linked sugars to the Fc domain which has certain advantages.

**Example 5: Generation of Agonistic or Antagonistic Antibodies:**

The above described soluble receptor forms can be used to immunize mice and to make monoclonal antibodies by conventional methods. The resultant mAbs that are  
10 identified by ELISA methods can be further screened for agonist activity either as soluble antibodies or immobilized on plastic in various in vitro cellular assays. Often the death of the HT29 cell line is a convenient system that is sensitive to signaling through many TNF receptors. If this line does not possess the receptor of interest, that full length receptor can be stably transfected into the HT29 line to now allow the  
15 cytotoxicity assay to work. Alternatively, such cells can be used in the Cytosensor apparatus to assess whether activation of the receptor can elicit a pH change that is indicative of a signaling event. TNF family receptors signal well in such a format and this method does not require one to know the actual biological events triggered by the receptor. The agonistic mAbs would be "humanized" for clinical use. This procedure  
20 can also be used to define antagonistic mAbs. Such mAbs would be defined by the lack of agonist activity and the ability to inhibit receptor-ligand interactions as monitored by ELISA, classical binding or BIAcore techniques. Lastly, the induction of chemokine secretion by various cells in response to an agonist antibody can form a screening assay.

25 **Example 6: Screening for Inhibitors of the Receptor-Ligand Interaction:**

Using the receptor-Ig fusion protein, one can screen either combinatorial libraries for molecules that can bind the receptor directly. These molecules can then be tested in an ELISA formatted assay using the receptor-Ig fusion protein and a soluble form of the ligand for the ability to inhibit the receptor-ligand interaction. This ELISA  
5 can be used directly to screen various natural product libraries etc. for inhibitory compounds. The receptor can be transfected into a cell line such as the HT29 line to form a biological assay (in this case cytotoxicity) that can then form the screening assay.

#### **Example 7: In vivo Tumor Growth Inhibition**

10 The effectiveness of BCMA-Ig as a tumor growth antagonist was tested using a number of different tumor cell lines grown in vivo. Athymic (Nu/Nu), immunodeficient mice were used for these studies, and tumor cells were implanted subcutaneously. For the SW480 tumor line, which grows aggressively, we implanted  $8 \times 10^5$  cells in 100 $\mu$ l pyrogen-free, sterile PBS. One control group was left untreated  
15 (n=5), while other groups were dosed with 100 $\mu$ gs control-Ig (n=6) or 100 $\mu$ gs BCMA-Ig (n=6) proteins. Dosing began just prior to implantation, with subsequent doses every 7 days thereafter. Tumor diameter was measured using a micrometer, and the volume is calculated using the formula  $vol = 4/3\pi r^3$ .

SW480 colon carcinoma tumors grow very quickly using the Nu/Nu mouse  
20 model, and palpable tumors were detected within 10 days. After 24 days the average control tumor volume was 0.3cm<sup>3</sup>, while the average volume of BCMA-Ig treated tumors was 0.19 cm<sup>3</sup>, a reduction of 46% in tumor burden. The colon carcinoma HT29 also grows aggressively in the Nu/Nu model. For these experiments  $1 \times 10^6$  cells in 100 $\mu$ l pyrogen-free, sterile PBS were implanted subcutaneously, and the dosing  
25 regimen was as described for SW480. Palpable tumors were detected after 7 days, and in the control groups most of the tumors-grew very rapidly. After 42 days the average tumor volume in the control groups (untreated and control-Ig treated, n=12) was 0.485cm<sup>3</sup>, while the average tumor size in the BCMA-Ig treated group (n=5) was 0.095cm<sup>3</sup>, a reduction of 80% in tumor burden. After 50 days 30% of the mice in the  
30 control group were scored as terminal due to tumor sizes greater than 1.5cm<sup>3</sup>, and the experiment was halted. In contrast to the control group 0% of the mice in the BCMA-Ig treated group were scored as terminal. These results are shown in table 2.

Table 2. Tumor volumes and lethality in the HT29 model after 50 days treatment.

	<u>control animals (untreated and control-Ig treated)</u>		<u>BCMA-Ig treated</u>	
	<u>tumor vol</u>	<u>terminal</u>	<u>tumor vol</u>	<u>terminal</u>
5	0.22	-	0.11	-
	0.22	-	0.32	-
	0.35	-	0.13	-
10	0.61	-	0.56	-
	0.73	-	0.33	-
	1.74	+		
	2.53	+		
	1.51	+		
15	0.90	-		
	0.44	-		
	0.32	-		
	<u>1.92</u>	<u>±</u>	—	—
	ave: 0.96	%: 30	ave: 0.29	%: 0
20				

This demonstrates a 70% reduction in average tumor volume and a significant effect on mortality in the HT29 model of tumor growth using BCMA-Ig treatment.



The lung carcinoma tumor line A549 grows more slowly than the colon carcinoma lines described above. For this cell line we implanted  $1 \times 10^6$  cells in 100 $\mu$ l pyrogen-free, sterile PBS, and treated using the regimen described previously. Palpable tumors were detected approximately 20 days after implantation. 50 days after tumor implantation the average tumor volume in the control groups (untreated and control-Ig treated; n=16) was 0.2cm<sup>3</sup> while the average tumor volume in the BCMA-Ig treated group (n=7) was 0.1cm<sup>3</sup>, a reduction of 50% in tumor volume. In the BCMA-Ig treated group 57% of the mice had a tumor of less than 0.1cm<sup>3</sup> after 50 days, while only 6% of the control treated mice retained such a small tumor burden. 60 days after tumor implantation the average tumor volume in the control group had increased to 0.3cm<sup>3</sup>. In contrast the average tumor volume in the BCMA-Ig treated group was still less than 0.2cm<sup>3</sup> (0.188).

For the murine NIH3T3 line, which also grows more slowly than the colon carcinoma lines, we implanted  $5 \times 10^6$  cells in 100 $\mu$ l pyrogen-free, sterile PBS, and treated as described above. The NIH3T3 cells form a fibrosarcoma tumor when implanted subcutaneously in Nu/Nu mice. After 4 weeks palpable tumors were detected, and in the control groups (n=11) these tumors expanded in volume over the next 10 days to reach an average size of 0.136cm<sup>3</sup>. In contrast the tumor volume in the BCMA-Ig-treated group (n=5) only reached a size of 0.03cm<sup>3</sup>, a 78% reduction in tumor burden. At day 48 after tumor implantation the average tumor volume in the controls groups had reached 1.6cm<sup>3</sup>, while the average tumor volume in the BCMA-Ig treated group was only 0.8cm<sup>3</sup>, a 50% reduction in tumor volume. By day 52, 82% (9/11) of the animals in the control groups had been scored as terminal based on a tumor volume of greater than 1.5cm<sup>3</sup>, leaving only 18% of the animals still alive. In contrast 40% (2/5) of the animals in the BCMA-Ig treated group had a tumor of such volume that they had to be sacrificed, leaving 60% of the animals still alive. These results are tabulated in Table 3.

Table 3. Survivorship data in the NIH3T3 model.

		<u>Days after implantation</u>			
5	<u>% survival</u>	38	42	48	52
	control	100	90	64	18
	BCMA-Ig	100	100	80	60
10					

The results showing the growth of NIH3T3 tumors over time are illustrated in Figure 13. The results showing the growth of SW480 tumors over time are illustrated in Figure 14. The results showing the growth of the HT29 tumors over time, and a scattergram showing individual animals on day 42 after tumor implantation, are illustrated in figure 15A. The results showing the growth of A549 tumors in individual animals on days 50 and 60 after tumor implantation are shown in Figure 15B.

The results for the tumor growth inhibition for the NIH3T3 tumor cell line are shown in Figure 13. The results for the tumor growth inhibition for the SW480 tumor cell line are shown in Figure 14. The results for the tumor growth inhibition for the HT29 and A549 tumor cell lines are shown in Figure 15.

#### **Example 8: BCMA-IgG Causes a reduction in the number of B cells in Normal Mice**

Eight-week-old female BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME).

Mice (3/group) received i.p. either PBS, 400  $\mu$ g of human BCMA-huIgG1 (hBCMA-Ig) fusion protein (supplied by Teresa Cachero, Biogen), or 400  $\mu$ g of purified human IgG (HuIgG) (Sandoz, Basel, Switzerland) on days -8, -5, -1 and +2. Mice received 100  $\mu$ l of 10% sheep red blood cells (SRBC) (Colorado Serum Company, Denver, CO) on day 0.

At the time of sacrifice blood was collected via cardiac puncture into tubes containing EDT, and red blood cells were lysed in a hypotonic buffer. Blood was also collected without EDTA for serum preparation. Single cell suspensions were prepared from spleens and mesenteric lymph nodes (MLN) and red blood cells were lysed in a hypotonic buffer. Flow cytometry was performed using PE-conjugated anti-CD45R/B220, anti-syndecan/CD138 and anti-B7.2, and FITC-conjugated anti-IgM and

anti-CD45R/B220. All mAbs were purchased from Pharmingen (San Diego, CA). Briefly, Fc receptors were blocked with 10  $\mu$ g/ml Fc Block (Pharmingen) for 15 min. on ice, followed by addition of PE- and FITC-conjugated mAbs and incubated on ice for 20-30 min. Cells were washed 1x and suspended in 0.5% paraformaldehyde. Cell  
5 fluorescence data were acquired on a FACSCalibur™ flow cytometer (Becton Dickinson, San Jose, CA) and analyzed using CELLQuest™ software (Becton Dickinson).

After treatment with hBCMA-Ig there was approximately a 50% reduction in the number of B cells in peripheral blood and in the peripheral lymphoid organs  
10 examined. B220<sup>high</sup> IgM<sup>low</sup> B cells accounted for 23.4% and 21.5% of cells in PBS-treated and HuIgG-treated mice, respectively, whereas this population represented only 9.9% of cells in hBCMA-Ig-treated mice. Plasma cells (syndecan/CD138+) appeared to be slightly decreased as well with 5.7% and 4.8% present in the blood of PBS-treated and HuIgG-treated mice, respectively, compared with 3.9% in hBCMA-Ig-treated  
15 mice. The B7.2 molecule was upregulated on 3.1% and 4.5% of B220+ cells in PBS-treated and HuIgG-treated mice, respectively, compared with 1.9% in hBCMA-Ig-treated mice.

In the spleen B220<sup>high</sup> B cells were markedly reduced in hBCMA-Ig-treated mice representing 18.8%, compared with 36.7% and 40% in PBS- and HuIgG-treated  
20 mice, respectively. This decline was observed in both IgM<sup>high</sup> and IgM<sup>low</sup> subpopulations (see Table 1). There was no change observed in the newly formed B cell compartment in the spleen, B220<sup>low</sup> IgM<sup>high</sup> (data not shown). Plasma cells (syndecan/CD138+) appeared to be slightly decreased as well with 3.3% and 3.4% present in the spleen of PBS-treated and HuIgG-treated mice, respectively, compared  
25 with 2.4% in hBCMA-Ig-treated mice.

The MLN exhibited a decline in B220+ B cells with 14.1% present in hBCMA-Ig-treated mice compared with 26.7% and 35.8% in PBS-treated and HuIgG-treated mice, respectively. The data are summarized in Table 3.

**Table 3.** B cell populations in hBCMA-Ig, PBS and HuIgG-treated mice<sup>1</sup>.

<u>Blood</u>	<u>B220<sup>high</sup> IgM<sup>low</sup></u>	<u>Syndecan</u>	<u>B7.2/B220<sup>low</sup></u>
PBS	23.4 ± 5.7	5.7 ± 1.5	3.1 ± 0.5
HuIgG	21.5 ± 4.5	4.8 ± 0.9	4.5 ± 1.0
HBCMA-Ig	9.9 ± 1.8	3.9 ± 0.6	1.9 ± 0.5
<u>Spleen</u>	<u>B220<sup>high</sup> IgM<sup>low</sup></u>	<u>B220<sup>high</sup> IgM<sup>+</sup></u>	<u>Syndecan</u>
PBS	27.8 ± 1.6	11.9 ± 1.6	3.3 ± 0.8
HuIgG	30.5 ± 2	11.8 ± 1.0	3.4 ± 0.7
HBCMA-Ig	10.6 ± 0.2	8.4 ± 0.2	2.4 ± 0.2
<u>MLN</u>	<u>B220<sup>+</sup></u>		
PBS	26.7		
HuIgG	35.8 ± 3.3		
HBCMA-Ig	14.1 ± 5.9		

<sup>1</sup> The mice were treated as described in the Materials and Methods section, and the data are given as percent ± standard

##### 5 Deviation

The decreased percentage of B7.2+ B cells in the blood and plasma cells in the blood and spleens of hBCMA-Ig-treated mice after immunization with SRBCs suggests that there is inhibition of B cell activation and/or maturation, and potentially increased elimination of activated B cells. A very minor percent of antigen-specific B cells would be activated and respond to any antigen, in this case SRBC. Because the hBCMA-Ig treatment resulted in such a dramatic reduction in the percent of B cells in all tissues examined, ~50%, the activity of hBCMA-Ig appears to also target resting, mature B cells.

It is therefore contemplated that BCMA fusion protein may be used as a therapeutic drug with clinical application in B cell-mediated diseases. Diseases would include those that are autoimmune in nature such as systemic lupus erythematosus,

myasthenia gravis, autoimmune hemolytic anemia, idiopathic thrombocytopenia purpura, anti-phospholipid syndrome, Chaga's disease, Grave's disease, Wegener's Granulomatosis, Poly-arteritis Nodosa and Rapidly Progressive Glomerulonephritis. The therapeutic agent would also have application in plasma cell disorders such as

5 multiple myeloma, Waldenstrom's macroglobulinemia, Heavey-chain disease, Primary or immunocyte-associated amyloidosis, and Monoclonal gammopathy of undetermined significance (MGUS). Oncology targets would include B cell carcinomas, leukemias, and lymphomas.

It will be apparent to those skilled in the art that various modifications and

10 variations can be made in the polypeptides, compositions and methods of the invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided that they come within the scope of the appended claims and their equivalents.

What is claimed is:

1. A method of treating a mammal for a condition associated with undesired cell proliferation, said method comprising administering to said mammal a therapeutically effective amount of a composition comprising an APRIL-R antagonist, wherein the APRIL-R antagonist comprises a polypeptide that antagonizes the interaction between APRIL and its cognate receptor or receptors, with a pharmaceutically acceptable recipient.
2. The method of claim 1 wherein the APRIL-R antagonist is selected from the group consisting of:
  - a) a soluble APRIL-R polypeptide;
  - b) a soluble chimeric molecule comprising a soluble APRIL-R polypeptide fused to a heterologous amino acid sequence; and
  - c) an anti-APRIL-R antibody homolog.
3. The method of claim 2 wherein the soluble APRIL-R polypeptide is selected from the group consisting of:
  - a) an isolated APRIL-R polypeptide variant having at least 80% amino acid sequence identity with native sequence APRIL-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:8 (Figure 3A) or a fragment thereof;
  - b) a isolated APRIL-R polypeptide variant having at least 80% amino acid sequence identity with amino acid residues 1-52 of SEQ ID NO:8 (Figure 3A) or a fragment thereof; and
  - c) a isolated APRIL-R polypeptide comprising amino acid residues 8-41 of SEQ ID NO:8 (Figure 3A) or a fragment thereof.
4. The method of claim 2 wherein the soluble chimeric molecule comprises:
  - a) a soluble APRIL-R polypeptide selected from the group consisting of:
    - i. an isolated APRIL-R polypeptide variant having at least 80% amino acid sequence identity with native sequence APRIL-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:8 (Figure 3A) or a fragment thereof;
    - ii. a isolated APRIL-R polypeptide variant having at least 80% amino acid sequence identity with amino acid residues 1-52 of SEQ ID NO:8 (Figure 3A) or a fragment thereof; and

- iii. a isolated APRIL-R polypeptide comprising amino acid residues 8-41 of SEQ ID NO:8 (Figure 3A) or a fragment thereof,
  - b) fused to a heterologous amino acid sequence.
- 5 5. The method of claim 4 wherein the heterologous amino acid sequence is from an IgG Fc domain of an immunoglobulin.
- 6. The method of claim 4 wherein the heterologous amino acid sequence is from a signal sequence of a secreted protein.
- 7. The method of claim 2 wherein the anti-APRIL-R antibody homolog comprises an antibody which binds to an APRIL-R polypeptide selected from the group  
10 consisting of:
  - a) an isolated APRIL-R polypeptide variant having at least 80% amino acid sequence identity with native sequence APRIL-R polypeptide comprising amino acid residues 1 to 184 of SEQ ID NO:8 (Figure 3A) or a fragment thereof;
  - 15 b) a isolated APRIL-R polypeptide variant having at least 80% amino acid sequence identity with amino acid residues 1-52 of SEQ ID NO:8 (Figure 3A) or a fragment thereof; and
  - c) a isolated APRIL-R polypeptide comprising amino acid residues 8-41 of SEQ ID NO:8 (Figure 3A) or a fragment thereof.
- 20 8. A method of treating a mammal for a condition associated with undesired cell proliferation, said method comprising administering to said mammal a therapeutically effective amount of two or more antagonists, wherein at least two of the antagonists include a first APRIL-R antagonist that antagonizes the interaction between APRIL and BCMA, and a second APRIL-R antagonist that  
25 antagonizes an interaction between APRIL and another cognate APRIL receptor or receptors that are not BCMA.
- 9. The method of claims 1 to 8, wherein the undesired cell proliferation is a carcinoma.
- 10. The method of claims 1 to 8, wherein the condition associated with undesired cell  
30 proliferation is cancer.
- 11. The methods of claims 1 to 8, wherein the mammal is a human.
- 12. A method of treating a patient having a carcinoma whose proliferation is modulated by APRIL comprising administering to said patient a therapeutically effective amount of a composition comprising an APRIL-R antagonist, wherein

the APRIL-R antagonist comprises a polypeptide that antagonizes the interaction between APRIL and APRIL-R.

13. The method of claim 9, wherein the carcinoma is selected from the group consisting of human lung carcinoma, colon carcinoma, breast carcinoma, prostate carcinoma, and other carcinomas whose proliferation is modulated by APRIL.
- 5



## Map of myc-murine APRIL construct pCCM213.10 for expression in Pichia pastoris

CCAAACG ATG AGA TTT CCT TCA ATT TTT ACT GCA GTT TTA TTC GCA TCC TCC GCT GCT CCA GTC AAC ACT ACA  
 GGTTCG TAC TCT AAA GGA AGT TAA AAA TGA CGT CAA AAT AAG CGT AGG AGG CGT AAT CGA CGA GGT CAG TTG TGA TGT  
 M R F P S I F T A V L F A A S S A L A A P V N T T  
  
 ACA GAA GAT GAA ACG GCA CAA ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA GAT TTA GAA GGG GAT TTC GAT GTT GCT GTT  
 TGT CTT CTA TGT TGC CGT GTT TAA GGC CGA CTT CGA CAG TAG CCA ATG AGT CTA AAT CTT CCC CTA AAG CTA CAA CGA CAA  
 T E D E T A Q I P A E A V I G Y S D L E G D F D V A V  
  
 TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG TTT ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG  
 AAC GGT AAA AGG TTG TCG TGT TTA TTG CCC AAT AAC AAA TAT TTA TGA TGA TAA CGG TCG TAA CGA CGA TTT CTT CTT CCC  
 L P F S N S T N N G L L F I N T T I A S I A A K E E G  
  
 GTA TCT CTC GAG AAA AGA GAA CAA AAA CTC ATT TCT GAG GAA GAT CTG AAT AAA GAG CTC CAC TCA GTC CTG CAT CTT GTT  
 CAT AGA GAG CTC TTT TCT GGT TTT GAG TAA AGA CTC CTT CTA GAC TTA TTT CTC GAG GTG AGT CAG GAC GTA GAA CAA

myc-tag >>>murine APRIL

V S L E K R E Q K L I S E E D L N K E L H S V L H L V  
 CCA GTT AAC ATT ACC TCC AAG GAC TCT GAC GTG ACA GAG GTG ATG TGG CAA CCA GTA CTT AGG CGT GGG AGA GGC CTG GAG  
 GGT CAA TTG TAA TGG AGG TTC CTG AGA CTG CAC TGT CTC CAC TAC ACC GTT GGT CAT GAA TCC GCA CCC TCT CCG GAC CTC  
 P V N I T S K D S D V T E V M W Q P V L R R G R G L E  
  
 GCC CAG GGA GAC ATT GTA CGA GTC TGG GAC ACT GGA ATT TAT CTG CTC TAT AGT CAG GTC CTG TTT CAT GAT GTG ACT TTC  
 CGG GTC CCT CTG TAA CAT GCT CAG ACC CTG TGA CCT TAA ATA GAC GAG ATA TCA GTC CAG GAC AAA GTA CTA CAC TGA AAG  
 A Q G D I V R V W D T G I Y L L Y S Q V L F H D V T F  
  
 ACA ATG GGT CAG GTG GTA TCT CGG GAA GGA CAA GGG AGA AGA GAA ACT CTA TTC CGA TGT ATC AGA AGT ATG CCT TCT TCT GAT  
 TGT TAC CCA GTC CAC CAT AGA GCC CTT CCT GGT CCC TCT TCT TGA GAT AAG GCT ACA TAG TCT TCA TAC GGA AGA CTA  
 T M G Q V V S R E G Q G R R E T L F R C I R S M P S D  
  
 CCT GAC GGT GCC TAC AAT AGC TGC TAC AGT GCA GGT GTC TTT CAT TTA CAT CAA GGG GAT ATT ATC ACT GTC AAA ATT CCA  
 GGA CTG GCA CGG ATG TTA TCG ACG ATG TCA CGT CCA CAG AAA GTA AAT GTA GTT CCC CTA TAA TAG TGA CAG TTT TAA GGT  
 P D R A Y N S C Y S A G V F H L H Q G D I I T V K I P  
  
 CGG GCA AAC GCA AAA CTT AGC CTT TCT CCG CAT GGA ACA TTC CTG GGG TTT GTG AAA CTA TGA GCGCGCGGAATTAATCGCCTTA  
 GCC CGT TTG CGT TTT GAA TCG GAA AGA GGC GTA CCT TGT AAG GAC CCC AAA CAC TTT GAT ACT CGCCGCGGCTTAATTAAGCGGAAT  
 R A N A K L S L S P H G T F L G F V K L

FIG. 1

Map Of Flag-Human APRIL Construct PS429 For Expression In Mammalian Cells

TTTAATCAAAAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC GAT TAC AAA GAC GAT GAC GAT  
AAATTAGTTTGT TAC CGA TAG TAG ATG ATG GAG TAG GAG GAC AAG TGG CGA CAC GCC CCG CTA ATG TTTT CTG CTA CTG CTA

**FLAG-tag**

>>> M	A	I	I	I	Y	L	I	L	L	F	T	A	V	R	G	D	Y	K	D	D	D	D
AAA	GGA	CCC	GGA	CAG	CTG	CAG	AAA	CAG	AAG	AAG	CAG	CAC	TCT	GTC	CTG	CAC	CTG	GTT	CCC	ATT	AAC	GCC
TTT	CCT	GGG	CCT	GTC	GAC	GTC	TTT	GTC	TTC	TTC	GTC	GTG	AGA	CAG	GAC	GTG	GAC	CAA	GGG	TAA	TTG	CGG

>>> human APRIL

K	G	P	G	Q	V	L	Q	K	Q	K	K	Q	Q	H	S	V	L	H	L	V	P	I	N	A
T	S	K	D	D	S	D	T	E	V	M	W	Q	Q	F	A	L	R	R	G	R	G	L	Q	A
ACC	TCC	AAG	GAT	GAC	TCC	GAT	ACA	GAG	GTG	ATG	TGG	CAA	CCA	GCT	GCT	CTT	AGG	CGT	GGG	AGA	GGC	CTA	CAG	GCC
TGG	AGG	TTC	CTA	CTG	AGG	CTA	CAC	CTC	CAC	TAC	ACC	GTT	GGT	CGA	GAA	TCC	GCA	CCC	TCT	CCG	GAT	GTC	CGG	

CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG AGC CAG GTC CTG TTT CAA GAC GTG ACT  
GTT CCT ATA CCA CAG GCT TAG GTC CTA CGA CCT CAA ATA GAC GAC ATA TCG GTC CAG GAC AAA GTT CTG CAC TGA  
Q G Y G V R I Q D A G V Y L L Y S Q V L F Q D V T

TTT ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG  
TAA AAG TGG TAC CCA GTC CAC CAC AGA GCT CTT CCG GTT CCT TCC GTC CTC CTC GAT AAG GCT ACA TAT TCT TCA TAC  
TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG

CCG TCC CAC CCG GAC CCG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG  
 GGG AGG GTG GGC CTG GCC CGG ATG TTG TCG ACG ATA TCG CGT CCA CAG AAG GTA AAT GTG GTT CCC CTA TAA GAC  
 P S H P D R A Y N S C V F H T H O G D T L

AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC GGA ACC TTC CTG GGG TTT GTG AAA CTG  
TCA CAG TAT TAA GGG GCC CGT TCC CGC TTT GAA TTG GAG AGA GGT GTA CCT TGG AAG GAC CCC AAA CAC TTT TTT GAC  
S V I I P R A R A R A K L L N L S P H G T F L G F V K L

'GA TCTAGAGGGCCC  
'CT AGATCTCCCGG

FIG. 2

FIG. 3A-1
FIG. 3A-2

FIG. 3A

Nucleotide sequence (sequence ID #7) and  
amino acid sequence (sequence id #8) of full length human BCMA.

sequence ID#7

1 atgttgcagatggctgggcagtgctcccaaatgaatatatttgacagtttgttgcatgcttgcatacccttgt  
tacaacgtctaccgacccgtcacgagggttttacttataaaactgtcaaacacgtacgaaacgtatggaaca

sequence ID#8

1> M L Q M A G Q C S Q N E Y F D S L L H A C I P C

73 caacttcgatgttcttctaataactcctcctctaacatgtcagcggttattgtaatgcaagtgtagaccaattca  
gttgaagctacaagaagattatgaggaggagattgtacagtcgcaataaacattacgttcacactgggttaagt

25> Q L R C S S N T P P L T C Q R Y C N A S V T N S

FIG. 3A-1

145 gtgaaaggaacgaatgcgattctctggacctgtttgggactgagcttaataattctttggcagttttcgtg  
cactttccttgcttacgctaagagacctggacaaacctgactcgaattattaaagaaacctgcaaaagcac  
49> V K G T N A I L W T C L G L S L I I S L A V F V  
217 ctaatgttttttgctaaggaagataagctctgaaccattaaaggacgagtttaaaacacaggatcaggtctc  
gattacaaaaacgattcccttctatttcgagacttggttaatttcctgctcaaatttttgtgtcctagtcagag  
73> L M F L L R K I S S E P L K D E F K N T G S G L  
289 ctgggcattggctaacttgacctggaaaaagagcaggactggatgataaattattcttcgagagggcctcgag  
gaccctaccgattgtaactggaccttttctcgtcctgaccactactttaataagaaggctctctccggagctc  
97> L G M A N I D L E K S R T G D E I I L P R G L E  
361 tacacggtggaagaatgcacctgtgaagactgcatcaagagcaaacgaaaggctgactctgaccattgcttt  
atgtgccaccttcttacgtggacacttctgacgtagtctcgtttggcttccagctgagactggtaacgaaa  
121> Y T V E E C T C E D C I K S K P K V D S D H C F  
433 cactcccagctatggaggaaggcgcaaccattcttgtcaccacgaaaaacgaatgactattgcaagagcctg  
ggtgaggggtcgataacctccttcgcgttggtgaagaacagtggtgcttttgcttactgataaacgttctcggac  
145> P L P A M E E G A T I L V T T K T N D Y C K S L  
505 ccagctgcttttgagtgtctacggagatagagaaatcaatttctgtaggtaa  
ggtcgacgaaactcacgatacctcctctatctctttagttaaagacgatccatt  
169> P A A L S A T E I E K S I S A R \*

FIG. 3A-2

FIG. 3B-1
FIG. 3B-2
FIG. 3B-3

FIG. 3B

1 ATGGAGACAG ACACACTCCT GTTATGGGTG CTGCTGCTCT GGGTTCAGG TTCCACTGGT  
 >1 M E T D T L L L W V L L L W V P G S T G

61 GACGTCACGA TGTTCAGAT GGCTGGGCAG TGCTCCCAA ATGAATATTT TGACAGTTTG  
 >21 D V T M L Q M A G Q C S Q N E Y F D S L

121 TTGCATGCTT GCATACCTTG TCAACTTCGA TGTTCCTCTA ATACTCCTCC TCTAACATGT  
 >41 L H A C I P C Q L R C S S N T P P L T C

181 CAGCGTTATT GTAATGCAAG TGTGACCAAT TCAGTGAAG GAGTCGACAA AACTCACACA  
 >61 Q R Y C N A S V T N S V K G V D K T H T

241 TGCCCCACCGT GCCCAGCACC TGAACCTCCTG GGGGACCGT CAGTCTTCCT CTTCCTCCCCA  
 >81 C P P C P A P E L L G G P S V F L F P P

FIG. 3B-1

301 AAACCCAAGG ACACCCTCAT GATCTCCCGG ACCCTGAGG TCACATGCCG GGTGGTGGAC  
 101 K P K D T L M I S R T P E V T C V V V D  
  
 361 GTGAGCCACG AAGACCCTGA GGTCAAGTTC AACTGGTACG TGGACGGCGT GGAGGTGCAT  
 121 V S H E D P E V K F N W Y V D G V E V H  
  
 421 AATGCCAAGA CAAAGCCCGG GGAGGAGCAG TACAACAGCA CGTACCGTGT GGTACAGCGTC  
 141 N A K T K P R E E Q Y N S T Y R V V S V  
  
 481 CTCACCGTCC TGCACCAGGA CTGGCTGAAT GGCAAGGAGT ACAAGTGCAA GGTCTCCAAC  
 161 L T V L H Q D W L N G K E Y K C K V S N  
  
 541 AAAGCCCTCC CAGCCCCCAT CGAGAAAACC ATCTCCAAAG CCAAGGGCA GCCCCGAGAA  
 181 K A L P A P I E K T I S K A K G Q P R E  
  
 601 CCACAGGTGT ACACCCTGCC CCCATCCCGG GATGAGCTGA CCAAGAACCA GGTACGCCCTG  
 201 P Q V Y T L P P S R D E L T K N Q V S L  
  
 661 ACCTGCCTGG TCAAAGGCTT CTATCCCAGC GACATCGCCG TGGAGTGGGA GAGCAATGGG  
 221 T C L V K G F Y P S D I A V E W E S N G

FIG. 3B-2

7/33

```

721 CAGCCGGAGA ACAACTACAA GACCACGCCCT CCCGTGTTGG ACTCCGACGG CTCCTTCTTC
>241 Q P E N N Y K T T P P V L D S D G S F F

781 CTCTACAGCA AGCTCACCGT GGACAAGAGC AGGTGGCAGC AGGGGAACGT CTTCTCATGC
>261 L Y S K L T V D K S R W Q Q G N V F S C

841 TCCGTGATGC ATGAGGCTCT GCACAACCAC TACACGCAGA AGAGCCTCTC CCTGTCTCCC
>281 S V M H E A L H N H Y T Q K S L S L S P

901 GGGAAA
>301 G K

```

Fig. 3B: Example of a gene encoding a huBCMA-huIgG1 fusion protein. Origin of nucleotide and amino acid sequence for hBCMA-hIgG1 fusion protein from expression vector pJST538 is as follows: signal peptide derived from a murine Ig kappa cDNA is encoded nucleotides 1-66 (amino acids 1-22); cysteine rich domain of human BCMA is boxed and encoded by nucleotides 70-222 (amino acids 24-74); hIgG1 is encoded by nucleotides 226-909 (amino acids 76-302); noncritical residues were introduced at the cloning junctions (amino acids 23 and 75). Arrowhead indicates predicted site of signal sequence cleavage.

FIG. 3B-3

8/33




FIG. 4A



9/33





FIG. 4B

10/33



A: 450ngs APRIL + IRRELEVANT RABBIT SERA  
B: RABBIT SERA 1532 CONTROL  
C: 450ngs APRIL + R1532

FIG. 4C

11/33





FIG. 5A

12/33



A: 450ngs APRIL + IRRELEVANT RABBIT SERA  
B: RABBIT SERA 1532 CONTROL  
C: 450ngs APRIL + R1532

FIG. 5B

13/33




FIG. 6A

14/33




FIG. 6B

15/33




FIG. 7A

16/33





FIG. 7B



17/33



A: UNSTAINED CELLS

B: NO PROTEIN CONTROL + BIOTINYLATED M2 ANTI-FLAG mAb

C: 1ug/ml FLAG-APRIL + BIOTINYLATED ISOTYPE CONTROL mAb

D: 1ug/ml FLAG-APRIL + BIOTINYLATED MW ANTI-FLAG mAb

FIG. 7C




FIG. 8A




FIG. 8B

19/33




FIG. 8D




FIG. 8C

IP: Fc  
Biot: hlgG-HRP

## Specificity of BCMA-Fc. 24.08.99





FIG. 9A-1






FIG. 9A-2

22/33



23/31





FIG. 9B-3

24/33

FIG. 10




Transfect 293T with indicated expression plasmid (Rec-Fc or Flag ligand) in 9 cm plate.



1= Blank  
 2= hBCMA  
 3= hLT β R05  
 4= hp80 TNFR

myc-mAPRIL



BIAcore3000

090199b.ble

FIG. 11A

- 1= Blank

2= hBCMA

3= hLT  $\beta$  R05

4= hp80 TNFR

FLAG-mBAFF




FIG. 11C





FIG. 11C


28/33



293EBNA CELLS TRANSFECTED WITH FULL LENGHT hBCMA WERE STAINED WITH 0, 40, 200, 1000, OR 5000 mg/ml myc-mAPRIL, RABBIT ANTI-APRIL ANTISERA (R1532), AND PE-LABELLED DONKEY ANTI-RABBIT IgG.

FIG. 12A

29/33



293EBNA CELLS TRANSFECTED WITH FULL LENGHT hBCMA WERE

A: RABBIT SERA (R1532) CONTROL

B: 200 ng/ml myc-mAPRIL + 1ug/ml DCMA-Ig

C: 200 ng/ml myc-mAPRIL

FIG. 12B

30/33




FIG. 13

31/33




FIG. 14

FIG. 15A
FIG. 15B

FIG. 15




FIG. 15A






FIG. 15B

## SEQUENCE LISTING

<110> Apotech R & D S.A.  
Biogen, Inc.

<120> April Receptor (BCMA) and Uses Thereof

<130> A083PCT

<140> not assigned yet

<141> 2000-10-05

<150> 60/215688

<151> 2000-06-30

<150> 60/181807

<151> 2000-02-11

<150> 60/157933

<151> 1999-10-06

<160> 12

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 736

<212> DNA

<213> murine

<400> 1

ccaaacgatg	agatttcctt	caattttttac	tgcagtttta	ttcgcagcat	cctccgcatt	60
agctgctcca	gtcaacacta	caacagaaga	tgaacggca	caaattccgg	ctgaagctgt	120
catcgggttac	tcagatttag	aaggggattt	cgatgttgct	gttttgccat	ttccaacag	180
cacaaataac	gggttattgt	ttataaatac	tactattgcc	agcattgctg	ctaaagaaga	240
aggggtatct	ctcgagaaaa	gagaacaaaa	actcatttct	gaggaagatc	tgaataaaga	300
gtccactca	gtcctgcac	ttgttccagt	taacattacc	tccaaggact	ctgacgtgac	360
agaggtgatg	tggcaaccag	tacttaggcg	tgggagaggc	ctggaggccc	agggagacat	420
tgtacgagtc	tgggacactg	gaatttatct	gctctatagt	caggtcctgt	ttcatgatgt	480
gactttcaca	atgggtcagg	tggatctctg	ggaaggacaa	gggagaagag	aaactctatt	540
ccgatgtatc	agaagtatgc	cttctgatcc	tgaccgtgcc	tacaatagct	gctacagtgc	600
aggtgtcttt	catttacatc	aaggggatat	tatcactgtc	aaaattccac	gggcaaacgc	660
aaaacttagc	ctttctccgc	atggaacatt	cctgggggtt	gtgaaactat	gagcggccgc	720
gaattaattc	gcctta					736

<210> 2

<211> 736

<212> DNA

<213> murine

<400> 2

ggtttgctac	tctaaaggaa	gttaaaaatg	acgtcaaaat	aagcgtcgta	ggaggcgtaa	60
tcgacgaggt	cagttgtgat	gttgctcttct	actttgccgt	gtttaaggcc	gacttcgaca	120

```

gtagccaatg agtctaaatc ttcccctaaa gctacaacga caaaacggta aaaggttgtc 180
gtgttttattg cccaataaca aatatttatg atgataacgg tcgtaacgac gatttcttct 240
tccccataga gagctctttt ctcttggttt tgagtaaaga ctccttctag acttatttct 300
cgagggtgagt caggacgtag aacaagggtca attgtaatgg aggttcctga gactgcactg 360
tctccactac accgttggtc atgaatccgc accctctccg gacctccggg tccctctgta 420
acatgctcag accctgtgac cttaaataga cgagatatca gtccaggaca aagtactaca 480
ctgaaagtgt taccaggtcc accatagagc ccttcctgtt ccctcttctc tttgagataa 540
ggctacatag tcttcatacg gaagactagg actggcacgg atgttatcga cgatgtcacg 600
tccacagaaa gtaaatgtag ttcccctata atagtgcacg ttttaagggtg cccggttgcg 660
ttttgaatcg gaaagaggcg taccttgtaa ggaccccaaa cactttgata ctcgccggcg 720
cttaattaag cggaaat 736

```

&lt;210&gt; 3

&lt;211&gt; 234

&lt;212&gt; PRT

&lt;213&gt; homo sapiens

&lt;400&gt; 3

```

Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser
1          5          10          15
Ala Leu Ala Ala Pro Val Asn Thr Thr Glu Asp Glu Thr Ala Gln
20          25          30
Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe
35          40          45
Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu
50          55          60
Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val
65          70          75          80
Ser Leu Glu Lys Arg Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn
85          90          95
Lys Glu Leu His Ser Val Leu His Leu Val Pro Val Asn Ile Thr Ser
100          105          110
Lys Asp Ser Asp Val Thr Glu Val Met Trp Gln Pro Val Leu Arg Arg
115          120          125
Gly Arg Gly Leu Glu Ala Gln Gly Asp Ile Val Arg Val Trp Asp Thr
130          135          140
Gly Ile Tyr Leu Leu Tyr Ser Gln Val Leu Phe His Asp Val Thr Phe
145          150          155          160
Thr Met Gly Gln Val Val Ser Arg Glu Gly Gln Gly Arg Arg Glu Thr
165          170          175
Leu Phe Arg Cys Ile Arg Ser Met Pro Ser Asp Pro Asp Arg Ala Tyr
180          185          190
Asn Ser Cys Tyr Ser Ala Gly Val Phe His Leu His Gln Gly Asp Ile
195          200          205
Ile Thr Val Lys Ile Pro Arg Ala Asn Ala Lys Leu Ser Leu Ser Pro
210          215          220
His Gly Thr Phe Leu Gly Phe Val Lys Leu
225          230

```

&lt;210&gt; 4

&lt;211&gt; 542

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 4

```
<210> 5
<211> 542
<212> DNA
<213> homo sapiens
```

```
<210> 6
<211> 172
<212> PRT
<213> homo sapiens
```

<400>	6														
Met	Ala	Ile	Ile	Tyr	Leu	Ile	Leu	Leu	Phe	Thr	Ala	Val	Arg	Gly	Asp
1				5					10					15	
Tyr	Lys	Asp	Asp	Asp	Lys	Gly	Pro	Gly	Gln	Val	Gln	Leu	Gln	Lys	
			20				25						30		
Gln	Lys	Lys	Gln	His	Ser	Val	Leu	His	Leu	Val	Pro	Ile	Asn	Ala	Thr
		35					40					45			
Ser	Lys	Asp	Asp	Ser	Asp	Val	Thr	Glu	Val	Met	Trp	Gln	Pro	Ala	Leu
	50				55					60					
Arg	Arg	Gly	Arg	Gly	Leu	Gln	Ala	Gln	Gly	Tyr	Gly	Val	Arg	Ile	Gln
65					70					75					80
Asp	Ala	Gly	Val	Tyr	Leu	Leu	Tyr	Ser	Gln	Val	Leu	Phe	Gln	Asp	Val
				85					90					95	
Thr	Phe	Thr	Met	Gly	Gln	Val	Val	Ser	Arg	Glu	Gly	Gln	Gly	Arg	Gln
			100					105					110		
Glu	Thr	Leu	Phe	Arg	Cys	Ile	Arg	Ser	Met	Pro	Ser	His	Pro	Asp	Arg
		115					120					125			
Ala	Tyr	Asn	Ser	Cys	Tyr	Ser	Ala	Gly	Val	Phe	His	Leu	His	Gln	Gly
	130					135				140					
Asp	Ile	Leu	Ser	Val	Ile	Ile	Pro	Arg	Ala	Arg	Ala	Lys	Leu	Asn	Leu
145					150					155					160
Ser	Pro	His	Gly	Thr	Phe	Leu	Gly	Phe	Val	Lys	Leu				

<210> 7  
 <211> 555  
 <212> DNA  
 <213> homo sapiens

<400> 7  
 atgttgacaga tggctgggca gtgctcccaa aatgaatatt ttgacagttt gttgcatgct 60  
 tgcatacctt gtcaacttcg atgttcttct aatactcctc ctctaacatg tcagcgttat 120  
 tgtaatgcaa gtgtgaccaa ttcagtgaag ggaacgaatg cgattctctg gacctgtttg 180  
 ggactgagct taataatttc tttggcagtt ttcgtgctaa tgtttttgct aaggaagata 240  
 agctctgaac cattaagga cgagttttaa aacacaggat caggtctcct gggcatggct 300  
 aacattgacc tggaaaagag caggactggt gatgaaatta ttcttccgag aggcctcgag 360  
 tacacggtgg aagaatgcac ctgtgaagac tgcacaaaga gcaaaccgaa ggtcgactct 420  
 gaccattgct ttccactccc agctatggag gaaggcgcaa ccattcttgt caccacgaaa 480  
 acgaatgact attgcaagag cctgccagct gctttgagtg ctacggagat agagaaatca 540  
 atttctgcta ggtaa 555

<210> 8  
 <211> 184  
 <212> PRT  
 <213> homo sapiens

<400> 8  
 Met Leu Gln Met Ala Gly Gln Cys Ser Gln Asn Glu Tyr Phe Asp Ser  
 1 5 10 15  
 Leu Leu His Ala Cys Ile Pro Cys Gln Leu Arg Cys Ser Ser Asn Thr  
 20 25 30  
 Pro Pro Leu Thr Cys Gln Arg Tyr Cys Asn Ala Ser Val Thr Asn Ser  
 35 40 45  
 Val Lys Gly Thr Asn Ala Ile Leu Trp Thr Cys Leu Gly Leu Ser Leu  
 50 55 60  
 Ile Ile Ser Leu Ala Val Phe Val Leu Met Phe Leu Leu Arg Lys Ile  
 65 70 75 80  
 Ser Ser Glu Pro Leu Lys Asp Glu Phe Lys Asn Thr Gly Ser Gly Leu  
 85 90 95  
 Leu Gly Met Ala Asn Ile Asp Leu Glu Lys Ser Arg Thr Gly Asp Glu  
 100 105 110  
 Ile Ile Leu Pro Arg Gly Leu Glu Tyr Thr Val Glu Glu Cys Thr Cys  
 115 120 125  
 Glu Asp Cys Ile Lys Ser Lys Pro Lys Val Asp Ser Asp His Cys Phe  
 130 135 140  
 Pro Leu Pro Ala Met Glu Glu Gly Ala Thr Ile Leu Val Thr Thr Lys  
 145 150 155 160  
 Thr Asn Asp Tyr Cys Lys Ser Leu Pro Ala Ala Leu Ser Ala Thr Glu  
 165 170 175  
 Ile Glu Lys Ser Ile Ser Ala Arg  
 180

<210> 9  
 <211> 483  
 <212> DNA  
 <213> homo sapiens

&lt;400&gt; 9

gttgaagcta	caagaagatt	atgaggagga	gattgtacag	tcgcaataac	attacgttca	60
cactgggttaa	gtcactttcc	ttgcttacgc	taagagacct	ggacaaaacc	tgactcgaat	120
tattaaagaa	accgtcaaaa	gcacgattac	aaaaacgatt	ccttctattc	gagacttggc	180
aatttctctgc	tcaaattttt	gtgtcctagt	ccagaggacc	cgtaccgatt	gtaactggac	240
cttttctcgt	cctgaccact	actttaataa	gaaggctctc	cggagctcat	gtgccacctt	300
cttacgtgga	cacttctgac	gtagtctctg	tttggtctcc	agctgagact	ggtaacgaaa	360
ggtgagggtc	gatacctcct	tccgcgttgg	taagaacagt	ggtgcttttg	cttactgata	420
acgttctcgg	acggtcgcag	aaactcacga	tgcctctatc	tctttagtta	aagacgatcc	480
att						483

&lt;210&gt; 10

&lt;211&gt; 483

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 10

caacttcgat	gttcttctaa	tactcctcct	ctaacatgtc	agcgttattg	taatgcaagt	60
gtgaccaatt	cagtgaagg	aacgaatgcg	attctctgga	cctgtttggg	actgagctta	120
ataatttctt	tggcagtttt	cgtgctaatt	tttttgctaa	ggaagataag	ctctgaacca	180
ttaaaggacg	agtttaaaaa	cacaggatca	ggtctcctgg	gcatggctaa	cattgacctg	240
gaaaaggagca	ggactggtga	tgaaattatt	cttccgagag	gcctcgagta	cacggtggaa	300
gaatgcacct	gtgaagactg	catcaagagc	aaaccgaagg	tcgactctga	ccattgcttt	360
ccactcccag	ctatggagga	agggcgcaacc	attcttgctc	ccacgaaaac	gaatgactat	420
tgcaagagcc	tgccagctgc	tttgagtgtc	acggagatag	agaaatcaat	ttctgctagg	480
taa						483

&lt;210&gt; 11

&lt;211&gt; 906

&lt;212&gt; DNA

&lt;213&gt; homo sapiens

&lt;400&gt; 11

atggagacag	acacactcct	gttatgggtg	ctgctgctct	gggttccagg	ttccactggc	60
gacgtcacga	tggtgcagat	ggctgggcag	tgctcccaaa	atgaatattt	tgacagtgtg	120
ttgcatgctt	gcataccttg	tcaacttcga	tggtcttcta	atactcctcc	tctaactatg	180
cagcgttatt	gtaatgcaag	tgtgaccaat	tcagtgaag	gagtcgacaa	aactcacaca	240
tgcccaccgt	gcccagcacc	tgaactcctg	gggggaccgt	cagtcttcct	cttcccccca	300
aaacccaagg	acaccctcat	gatctcccg	acccctgagg	tcacatgcgt	ggtggtggac	360
gtgagccaag	aagaccctga	ggtcaagtgc	aactggtagc	tggaaggcgt	ggaggtgcat	420
aatgccaaaga	caaagccgcg	ggaggagcag	tacaacagca	cgtaccgtgt	ggtcagcgtc	480
ctcacgcgtc	tgaccagga	ctggctgaat	ggcaaggagt	acaagtgcaa	ggtctccaac	540
aaagccctcc	cagcccccat	cgagaaaacc	atctccaaag	ccaaagggca	gccccgagaa	600
ccacaggtgt	acaccctgcc	cccattcccg	gatgagctga	ccaagaacca	ggtcagcctg	660
acctgcctgg	tcaaaggctt	ctatcccagc	gacatcgccg	tggaagtggga	gagcaatggg	720
cagccggaga	acaactacaa	gaccacgcct	cccgtgttgg	actccgacgg	ctccttcttc	780
ctctacagca	agctcaccgt	ggacaagagc	aggtggcagc	aggggaacgt	cttctcatgc	840
tccgtgatgc	atgaggctct	gcacaaccac	tacacgcaga	agagcctctc	cctgtctccc	900
gggaaa						906

&lt;210&gt; 12

&lt;211&gt; 302

&lt;212&gt; PRT

&lt;213&gt; homo sapiens

&lt;400&gt; 12

Met	Glu	Thr	Asp	Thr	Leu	Leu	Leu	Trp	Val	Leu	Leu	Leu	Trp	Val	Pro
1				5					10					15	
Gly	Ser	Thr	Gly	Asp	Val	Thr	Met	Leu	Gln	Met	Ala	Gly	Gln	Cys	Ser
			20					25					30		
Gln	Asn	Glu	Tyr	Phe	Asp	Ser	Leu	Leu	His	Ala	Cys	Ile	Pro	Cys	Gln
			35				40					45			
Leu	Arg	Cys	Ser	Ser	Asn	Thr	Pro	Pro	Leu	Thr	Cys	Gln	Arg	Tyr	Cys
	50					55					60				
Asn	Ala	Ser	Val	Thr	Asn	Ser	Val	Lys	Gly	Val	Asp	Lys	Thr	His	Thr
65					70					75					80
Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe
				85					90					95	
Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro
			100					105						110	
Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val
		115					120					125			
Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr
	130					135					140				
Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val
145					150					155					160
Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys
				165				170						175	
Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser
			180					185						190	
Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro
		195					200					205			
Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val
	210					215					220				
Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly
225					230					235					240
Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp
				245					250					255	
Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp
			260					265						270	
Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His
		275					280					285			
Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys		
	290					295					300				

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 12965 A (BIOGEN, INC.) 18 March 1999 (1999-03-18) cited in the application page 1, line 4 - line 10 page 11, line 10 - line 23 page 15, line 13 - line 23 page 16, line 11 - page 17, line 11 page 24, line 7 - page 25, line 28 page 26, line 1 - line 29; example 3 ---	1-13
X	HAHNE M ET AL: "APRIL, a new ligand of the tumor necrosis factor family, Stimulates tumor cell growth" JOURNAL OF EXPERIMENTAL MEDICINE, JP, TOKYO, vol. 188, 21 September 1998 (1998-09-21), pages 1185-1190, XP002093077 ISSN: 0022-1007 the whole document --- -/--	1,2,9-13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

20 February 2001

Date of mailing of the international search report

06/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B



## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHRISTINE MADRY ET AL.: "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily" INTERNATIONAL IMMUNOLOGY, vol. 10, no. 11, November 1998 (1998-11), pages 1693-1702, XP000982102 abstract</p> <p>page 1696, left-hand column, paragraph 2  -right-hand column, paragraph 1  page 1696, right-hand column, last paragraph -page 1697, left-hand column, paragraph 1; figure 2  page 1698, right-hand column, paragraph 1  page 1698, right-hand column, paragraph 3  -page 1699, left-hand column, paragraph 1  page 1699, right-hand column, last paragraph -page 1701, left-hand column, last paragraph</p> <p>---</p>	1-4,7, 11,12
P,X	<p>JEFFREY S. THOMPSON ET AL.: "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, no. 1, 3 July 2000 (2000-07-03), pages 129-135, XP002160850 abstract</p> <p>page 129, right-hand column, paragraph 2  -page 130, left-hand column, paragraph 2  page 131, left-hand column, paragraph 2  -page 132, right-hand column, paragraph 1  page 133, left-hand column, paragraph 2  -page 134, right-hand column, paragraph 2</p> <p>---</p>	1-13
P,X	<p>JEFFREY THOMPSON ET AL.: "BAFF interacts with the orphan receptor, BCMA" SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 51, no. 1, June 2000 (2000-06), page 65 XP000971932 abstract 2.6</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-5,7,12

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	HONG-BING SHU ET AL.: "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 9156-9161, XP002160851 WASHINGTON US abstract page 9160, left-hand column, last paragraph -page 9161, right-hand column, paragraph 2 ---	1-8,12
P,X	WO 00 40716 A (ZYMOGENETICS, INC.) 13 July 2000 (2000-07-13) page 2, line 15 -page 6, line 6 page 46, line 16 -page 54, line 36 page 57, line 21 -page 59, line 23 page 74, line 9 - line 34; examples 11-17 Sequence listing SEQ ID NO:7, 8 ---	1-5,7, 9-13
P,X	WO 00 50633 A (THE GENERAL HOSPITAL CORPORATION) 31 August 2000 (2000-08-31) page 6, line 14 -page 8, line 3 page 11, line 25 -page 12, line 3 page 27, line 14 -page 29, line 6 ---	1-7,9-13
P,X	GANG YU ET AL.: "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity" NATURE IMMUNOLOGY, vol. 1, no. 3, September 2000 (2000-09), pages 252-256, XP000982268 page 252, right-hand column, paragraph 2 page 254, left-hand column, paragraph 1 -right-hand column, paragraph 2 page 255, left-hand column, paragraph 1 - paragraph 2 page 255, left-hand column, paragraph 4 -right-hand column, paragraph 2 ---	1-13
P,X	JANE A. GROSS ET AL.: "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease" NATURE, vol. 404, 27 April 2000 (2000-04-27), pages 995-999, XP002140939 the whole document --- -/--	1-5,7,12

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	XING-ZHONG XIA ET AL.: "TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, no. 1, 3 July 2000 (2000-07-03), pages 137-143, XP000982104 page 138, left-hand column, paragraph 3 page 140, left-hand column, paragraph 2 -right-hand column, paragraph 2 page 142, right-hand column, paragraph 2	1-8, 11, 12
E	WO 00 68378 A (NATIONAL JEWISH MEDICAL AND RESEARCH CENTER) 16 November 2000 (2000-11-16) page 2, line 28 -page 3, line 2 page 5, line 29 -page 6, line 31 page 7, line 13 - line 20 page 7, line 29 -page 8, line 11 page 12, line 25 -page 13, line 15 page 32, line 12 -page 38, line 2 page 44, line 12 -page 45, line 23 page 48, line 1 - line 14; example 4 sequence listing SEQ ID NO:10, 11	1-4, 7, 8, 11, 12

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: Partially 1, 8-13

Present claims 1, and 8-13 relate to a compound defined by reference to a desirable characteristic or property, namely antagonizing the interaction between APRIL and its receptors. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in the description, i.e. soluble APRIL-R polypeptides, chimeric molecules comprising a soluble APRIL-R polypeptide and anti-APRIL-R antibodies.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9912965 A	18-03-1999	AU 9315298 A	29-03-1999
		AU 9316298 A	29-03-1999
		BR 9812433 A	26-09-2000
		BR 9812634 A	22-08-2000
		CN 1269832 T	11-10-2000
		CN 1270632 T	18-10-2000
		EP 1012270 A	28-06-2000
		EP 1027431 A	16-08-2000
		NO 20001240 A	10-05-2000
		NO 20001242 A	11-05-2000
		PL 339463 A	18-12-2000
		SK 3542000 A	14-08-2000
		WO 9912964 A	18-03-1999
WO 0040716 A	13-07-2000	AU 2408400 A	24-07-2000
WO 0050633 A	31-08-2000	AU 3380200 A	14-09-2000
WO 0068378 A	16-11-2000	NONE	